Clay interlaced yeast compositions and methods of utilizing the same

ABSTRACT

The present invention relates to compositions comprising yeast cells and/or yeast cell components and methods for producing and utilizing the same. In particular, the invention provides novel yeast comprising altered cell wall structure (e.g., clay and/or clay component(s) integrated (e.g., interlaced) into cell wall(s) and/or cell wall(s) comprising altered glucan:mannan ratio), methods of producing the same, compositions comprising and/or derived from the same, and methods of using the same (e.g., to sequester and/or adsorb bacteria and toxins). Compositions and methods of the invention find use in a variety of applications including dietary (e.g., admixing with feedstuffs or otherwise feeding to animals), therapeutic, prophylactic (e.g. admixing with bedding sources and/or other materials that come into contact with animals, usage during food and beverage processing and manufacture, and usage during filtration of liquids) as well as research applications.

This application is a Divisional of U.S. patent application Ser. No.12/856,407 filed Aug. 13, 2010, which is a Continuation-In-PartApplication of U.S. patent application Ser. No. 12/687,833 filed Jan.14, 2010, which claims priority to U.S. Provisional Application61/144,620 filed Jan. 14, 2009, each of which is hereby incorporated byreference in its entirety.

FIELD OF THE INVENTION

The present invention relates to compositions comprising yeast cellsand/or yeast cell components and methods for producing and utilizing thesame. In particular, the invention provides novel yeast comprisingaltered cell wall structure (e.g., clay and/or clay component(s)integrated (e.g., interlaced) into cell wall(s) and/or cell wall(s)comprising altered glucan:mannan ratio), methods of producing the same,compositions comprising and/or derived from the same, and methods ofusing the same (e.g., to sequester and/or adsorb bacteria and toxins).Compositions and methods of the invention find use in a variety ofapplications including dietary (e.g., admixing with feedstuffs orotherwise feeding to animals), therapeutic, prophylactic (e.g. admixingwith bedding sources and/or other materials that come into contact withanimals, usage during food and beverage processing and manufacture, andusage during filtration of liquids) as well as research applications.

BACKGROUND OF THE INVENTION

Fungi are ubiquitous worldwide, and inconspicuous as they are mostcommonly microscopically small. Mycotoxins are secondary metabolitessecreted by fungi. Mycotoxins are toxic and/or carcinogenic compoundsproduced by various fungal species that grow on various agriculturalcommodities. Examples of mycotoxins, include but are not limited toaflatoxins, fumonisins, ochratoxin A, deoxynivalenol (a.k.a. “DON” or“vomitoxin”), patulin, and zearalenone. Myotoxins are often produced incereal grains as well as forages before, during and after harvest. Somemycotoxins are lethal, some cause identifiable diseases or healthproblems, some weaken the immune system without producing symptomsspecific to that mycotoxin, some act as allergens or irritants, and somehave no known effect on animals or humans. The greatest economic impactof mycotoxin contamination is felt by crop and poultry producers, aswell as food and feed producers. Mycotoxins can appear in the food chainas a result of fungal infection of plant products, and can either beeaten directly by humans, or introduced by contaminating livestockfeedstuff(s). Mycotoxins contaminate organic materials (e.g. bedding) aswell as water, and greatly resist decomposition during digestion so theyremain in the food chain in edible products (e.g. meat, eggs and dairyproducts). No region of the world escapes mycotoxins and their negativeimpact on animal and human health. The evolution of global trading offeedstuffs increases the chances that blends of grains will result incombinations of mycotoxins in a given diet and that unusual andunsuspected mycotoxins will be present in a given region regardless ofits climate condition.

Strategies used to avoid mycotoxin occurrence involve controllingelements that permit mycotoxin production, controlling mold growth, aswell as practicing quality control of food and feeds via adequatesampling, detection and quantification methodology. However, mycotoxincontamination is unavoidable.

In order to reduce the negative effects of mycotoxins, inorganicmaterials such as clays, bentonites, and aluminosilicates, known fortheir adsorptive properties, have historically been added to feedstuffs.Feedstuff-additives, in large quantities, sequester some mycotoxins inthe gastrointestinal tract of the animal and minimize their toxiceffects. However, additives hinder the absorption of many beneficialnutrients that are important to animals such as vitamins, minerals, andamino acids thereby decreasing the nutrient density of the diet.Moreover, feedstuff additives, particularly in animal feces, have anextremely detrimental environmental impact.

Chemical agents such as acids, bases (e.g., ammonia, caustic soda),oxidants (e.g., hydrogen peroxide, ozone), reducing agents (e.g.,bisulphites), chlorinated agents and formaldehyde, have been used todegrade mycotoxins in contaminated feeds, particularly aflatoxins (See,e.g., Hagler 1991; Phillips et al 1994; Lemke et al 2001). However,these techniques are not efficient, are expensive, generate asignificant amount of chemical waste, and are generally unsafe.

Certain strains of lactic acid bacteria, propionibacteria andbifidobacteria have cell wall structures that bind mycotoxins (See,e.g., Ahokas et al 1998; El-Nemazi et al 1998; Yoon et al 1999) andlimit their bioavailability in the animal body. However, thesebiological processes are generally slow, produce toxic metabolites, andare inefficient.

SUMMARY OF THE INVENTION

In some embodiments, the present invention provides a yeast cellcomprising a yeast cell wall comprising clay or a clay componentinterlaced into the yeast cell wall. In some embodiments, the yeast cellis cultivated in a cell culture medium comprising clay. In someembodiments, the clay is a mineral clay or synthetic clay belonging tothe silicate group. In some embodiments, the clay is selected from azeolite, a bentonite, an aluminosilicate, a montmorillonite, a smectite,a kaolinite, an organoclay and mixtures thereof. In some embodiments,the clay is an aluminosilicate clay. In some embodiments, the amount ofclay in the cell culture medium is from about 0.125% to about 4.0%. Insome embodiments, the amount of clay in the cell culture medium is from0.125% to 4.0%. In some embodiments, the amount of clay in the cellculture medium is from about 0.5% to about 2.0%. In some embodiments,the amount of clay in the cell culture medium is from 0.5% to 2.0%. Insome embodiments, the yeast is selected from Saccharomyces, Candida,Kluyveromyces, Torulaspora and combinations thereof. In someembodiments, the yeast is Saccharomyces cerevisiae.

In some embodiments, the present invention provides compositioncomprising a clay or clay component interlaced yeast cell wall extract.In some embodiments, the clay or clay component interlaced yeast cellwall extract is derived from a yeast cell cultivated in growth mediumcomprising a clay. In some embodiments, glass beads and a bead beaterare utilized to prepare the yeast cell wall extract. In someembodiments, enzymatic treatment is utilized to prepare the yeast cellwall extract. In some embodiments, the clay or clay component interlacedyeast cell wall extract is added to a feedstuff. In some embodiments,the feedstuff is selected from a Total Mixed Ration (TMR), a forage, apellet, a concentrate, a premix, a coproduct, grain, distiller grain,molasses, fiber, fodder, grass, hay, kernel, leaves, meal, solubles, anda supplement. In some embodiments, the clay or clay component interlacedyeast cell wall extract is added to organic material. In someembodiments, the clay or clay component interlaced yeast cell wallextract is added to water. In some embodiments, a liquid is filteredthrough the clay or clay component interlaced yeast cell wall extract.In some embodiments, the liquid is a juice, water, beer or wine. In someembodiments, the composition is formulated for feeding to any member ofKingdom Animalia. In some embodiments, the member of Kingdom Animalia isselected from avian, bovine, porcine, equine, ovine, and caprine,piscines, shellfish, camelids, feline, canine, and rodent species. Insome embodiments, the clay or clay component interlaced yeast cell wallextract sequester one or more mycotoxins. In some embodiments, themycotoxin is selected from Aflatoxins, Zearalenone, Trichothecenes,Fumonisins, and Ochratoxins. In some embodiments, the mycotoxin isselected from of acetoxyscirpenediol, acetyldeoxynivalenol,acetylnivalenol, acetylneosolaniol, acetyl T-2 toxin, extended to allaflatoxins, aflatoxin B1, B2, G1 and G2, aflatrem, altenuic acid,alternariol, austdiol, austamide, austocystin, avenacein+1,beauvericin+2, bentenolide, brevianamide, butenolide, calonectrin,chaetoglobosin, chaetocin, chaetomin, citrinin, citreoviridin,cochliodinol, cytochalasins, cyclopiazonic acid, deacetylcalonectrin,deactylneosolaniol, deoxynivalenol diacetate, deoxynivalenolmonoacetate, diacetoxyscirpenol, destruxin B, emestrin, enniatins,extended to all ergot alkaloids toxins and endophytes such as ergine,ergocornine, ergocristine, ergocryptine, ergometrine, ergonine,ergosine, ergotamine, ergovaline, lysergol, lysergic acid, and relatedepimers, fructigenin+1, fumagilin, fumonisins, fumonisins A1, A2, B1 andB2 and B3, fusarenon-X, fusarochromanone, fusaric acid, fusarin,gliotoxin, HT-2 toxin, hyalodendrin, ipomeanine, islanditoxin,isofumigaclavines A and B, lateritin+1, leptosin, lycomarasmin+1,malformin, maltoryzine, moniliformin, monoacetoxyscirpenol, mycophenolicacid, neosolaniol, nivalenol, NT-1 toxin, NT-2 toxin, extended to allochratoxins, oosporein, oxalic acid, paspalitrem A and B, patulin,penicillic acid, penitrem, phomopsins, PR-toxin, roridin E, roquefortineA and B, rubratoxin, rubroskyrin, rubrosulphin, rugulosin, sambucynin+1,satratoxins, F, G, H, scirpentriol, sirodesmin, slaframine, sporidesmin,sterigmatocystin, swainsonine, T-1 toxin, T-2 toxin, tenuazoic acid,triacetoxyscirpendiol extended to all trichothecenes, trichodermin,trichothecin, trichoverrins, trichoverrols, tryptoquivalene, verrucarin,verruculogen, verticillins, viopurpurin, viomellein, viriditoxin,wortmannin, xanthocillin, yavanicin+1, zearalenols, zearalanones,zearalenone, α, β, zearalanone, α, β, zeranol and subfamilies and/orderivatives of the same, and/or conjugates.

In some embodiments, the present invention provides a compositionscomprising a clay or clay component interlaced yeast cell wall extract,wherein the clay or clay component interlaced yeast cell wall extract ispresent in an amount effective to sequester mycotoxins. For example, insome embodiments, the clay or clay component interlaced yeast cell wallextract is present in an amount of about 0.0125% to about 10% by weightof a feedstuff. In some embodiments, the clay or clay componentinterlaced yeast cell wall extract is present in an amount of about0.0125% to about 4.0% by weight of a feedstuff. The present invention isnot limited by the type of feedstuff.

In some embodiments, the present invention provides a method forreducing bioavailability of mycotoxins to an animal or human comprising:(a) providing: (i.) a composition comprising a clay or clay componentinterlaced yeast cell wall extract, and (ii) a material consumed byanimal or human; (b) incorporating the clay or clay component interlacedyeast cell wall extract into the material to produce a clay or claycomponent interlaced yeast cell wall extract incorporated material; and(c) allowing the animal or human to consume the clay or clay componentinterlaced yeast cell wall extract incorporated material. In someembodiments, the material is a feedstuff. In some embodiments, about0.0125% to about 0.4% by weight of the composition comprising a clay orclay component interlaced yeast cell wall extract is added to afeedstuff. In some embodiments, the material is bedding. In someembodiments, the about 0.0125% to about 99.0% of the compositioncomprising a clay or clay component interlaced yeast cell wall extractis added by weight to the bedding. In some embodiments, material is aliquid. In some embodiments, about 0.0125% to about 99.0% of thecomposition comprising a clay or clay component interlaced yeast cellwall extract is added by weight to the liquid. In some embodiments, theanimal is selected from of avian, bovine, porcine, equine, ovine, andcaprine, piscines, shellfish, camelids, feline, canine, and rodentspecies. In some embodiments, the composition comprising a clay or claycomponent interlaced yeast cell wall extract sequesters one or moretypes of mycotoxins. In some embodiments, the mycotoxins are Aflatoxins,Zearalenone, Trichothecenes, Fumonisins, Ochratoxins, or combinationsthereof. In some embodiments, the present invention further providesincorporating an additional agent into the clay or clay componentinterlaced yeast cell wall extract incorporated material, wherein theagent is selected from an esterase, epoxidase, yeast and/or bacterialstrain.

In some embodiments, the present invention provides a method ofproducing a commercial-scale quantity of clay or clay componentinterlaced yeast cell wall extract comprising: (a) providing: (i) yeaststarter culture and (ii) yeast cell culture media, wherein the yeastcell culture media comprises the required nutrients for yeast growth anda clay or clay component; (b) introducing the yeast starter culture intothe yeast cell culture media; (c) incubating the yeast in anindustrial-scale fermenter under conditions configured to allow yeastgrowth, wherein the yeast incorporate the clay or clay component intothe yeast cell wall during growth; (d) adding anti-foaming agent to thefermenter; (e) lysing the clay or clay component interlaced yeast cellswalls; and (f) separating the clay or clay component interlaced yeastcells walls from the other yeast components. In some embodiments, theyeast is selected from Saccharomyces, Candida, Kluyveromyces,Torulaspora or combinations thereof. In some embodiments, the clay is amineral clay or synthetic clay belonging to the silicate group. In someembodiments, the clay is a zeolite, a bentonite, an aluminosilicate, amontmorillonite, a smectite, a kaolinite, an organoclay or mixturethereof. In some embodiments, the clay is an aluminosilicate clay. Insome embodiments, the amount of clay in the cell culture medium is fromabout 0.125% to about 4.0%. In some embodiments, the amount of clay inthe cell culture medium is from about 0.5% to about 2.0%. In someembodiments, the amount of clay in the cell culture medium is from0.125% to 4.0%. In some embodiments, the amount of clay in the cellculture medium is from 0.5% to 2.0%. In some embodiments, theindustrial-scale fermenter is between one thousand and five millionliters. In some embodiments, the anti-foaming agent is added toalleviate effects of the clay on the incubation process. In someembodiments, the anti-foaming agent is a nonsilicone molecular defoamer,oil-based defoamer, powder defoamer, water-based defoamer, siliconebased defoamer, polyethylene glycol-based defoamer, polypropyleneglycol-based defoamer, or alkyl polyacrylates. In some embodiments, theanti-foaming agent is a nonsilicone molecular defoamer. In someembodiments, the lysing comprises glass beads, a bead beater and/orenzymatic treatment.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows A) a depiction of a yeast cell with clay and/or claycomponents interlaced into the yeast cell wall, and B) a comparativedescription of (a) the yeast cell wall of a yeast cell cultivated in theabsence of clay and (b) the yeast cell wall of a yeast cellgrown/cultivated in the presence of clay.

FIG. 2 shows a scanning electron micrograph of (A) a bentonite clay(Fluka); (B) yeast cells cultivated in the absence of clay and aclose-up of the glucan portion of the yeast cell wall; (C1) yeast cellscultivated in the presence of 2% bentonite clay with detail of aconglomerate formation of several yeast cells trapped in the lamellarstructure of bentonite; (C2) yeast cells cultivated in the presence of2% bentonite clay with detail of an inclusion of the clay directly inthe yeast cell wall structure.

FIG. 3 provides characteristics of yeast cell wall extracts preparedutilizing glass beads and a minibead beater from yeast cells: cultivatedin the absence of clay (Yeast Cell Wall “YCW” only), yeast cellscultivated in the presence of 0.5% clay (YCW+5%), yeast cells cultivatedin the presence of 1% clay (YCW+1.0%), and yeast cells cultivated in thepresence of 2.0% clay. Additionally, the percentages of adsorption ofthe mycotoxin zearalanone for each of the samples.

FIG. 4 provides characteristics of yeast cell wall extracts preparedutilizing protease cutting from yeast cells cultivated in the absence ofclay (YCW only), yeast cells cultivated in the presence of 1% clay(YCW+1.0%), and yeast cells cultivated in the presence of 2.0% clay.

FIG. 5 depicts the anatomy of a yeast cell.

FIG. 6 shows the composition of two batches of CIYCW produced at asemi-industrial scale.

FIG. 7 shows sequestration efficacy results obtained with the yeast cellwall semi-industrial scale, with and without smectite clay and havingbeen or not extracted with enzyme hydrolysis. The level of inclusion ofthe sequestrants product for AFB1 and ZEA were respectively of 0.1 and0.4% in the reaction medium that was maintained at a constant pH of 4.0.The assay was performed under orbital agitation during 90 min at 37° C.and the amount of bound toxin evaluated using HPLC equipped with afluorescent detector.

FIG. 8 shows sequestering efficacy results obtained with the yeast cellwall production with smectite clay and having been extracted with enzymehydrolysis. The level of inclusion of the sequestrants product for AFB1and ZEA were respectively of 0.1 and 0.4% in the reaction medium thatwas maintained at a constant pH of 4.0. The assay was performed underorbital agitation during 90 min at 37° C. and the amount of bound toxinevaluated using HPLC equipped with a fluorescent detector.

FIG. 9 shows adsorption results obtained with the different yeast cellwall coming from three strains grown with or without clay MBB02 andhaving been or not extracted with enzyme hydrolysis. The level ofinclusion of the sequestrants product for AFB1 and ZEA were respectivelyof 0.1 and 0.4% in the reaction medium that was maintained at a constantpH of 4.0. The assay was performed under orbital agitation during 90 minat 37° C. and the amount of bound toxin evaluated using HPLC equippedwith a fluorescent detector.

DEFINITIONS

As used herein, the term “yeast” and “yeast cells” refers to eukaryoticmicroorganisms classified in the kingdom Fungi, having a cell wall, cellmembrane and intracellular components. Yeasts do not form a specifictaxonomic or phylogenetic grouping. Currently about 1,500 species areknow; it is estimated that only 1% of all yeast species have beendescribed. The term “yeast” is often taken as a synonym for S.cerevisiae, but the phylogenetic diversity of yeasts is shown by theirplacement in both divisions Ascomycota and Basidiomycota. The buddingyeasts (“true yeasts”) are classified in the order Saccharomycetales.Most species of yeast reproduce asexually by budding, although somereproduce by binary fission. Yeasts are unicellular, although somespecies become multicellular through the formation of a string ofconnected budding cells known as pseudohyphae, or false hyphae. Yeastsize can vary greatly depending on the species, typically measuring 3-4μm in diameter, although some yeast can reach over 40 μm.

As used herein, the term “yeast cell wall” also referred to as “YCW”refers to the cell wall of a yeast organism that surrounds the plasmicmembrane and the intracellular components of the yeast. Yeast cell wallincludes both the outer layer (mainly mannan) and the inner layer(mainly glucan and chitin) of the yeast cell wall. A function of thecell wall is to provide structure and protect the yeast interior (itsmetabolic activity center). Signaling and recognition pathways takeplace in the yeast cell wall. The composition of yeast cell wall variesfrom strain to strain and according to growth conditions of yeast.

As used herein, the term “yeast cell wall extract” refers to the yeastcell wall of yeast that has been ruptured or “lysed” (e.g., during arupture and lysing stage) and separated from the soluble intracellularcomponents of the yeast cell.

The term “isolated” when used in relation to a yeast cell wall, as in“an isolated yeast cell wall” or “isolated clay integrated yeast cellwall” or “isolated yeast cell wall comprising altered glucan:mannanstructure” refers to a yeast cell wall or component thereof that isidentified and separated from at least one component with which it isordinarily associated in its natural source. Thus, an isolated yeastcell wall is such present in a form or setting that is different fromthat in which it is found in nature (e.g., that is separate fromintracellular components of yeast). In contrast, non-isolated yeast cellwall is a yeast cell wall or component thereof found in the state theyexist in nature. In some embodiments, isolated yeast cell wall is usedto describe yeast cell wall extract.

As used herein, the term “purified” or “to purify” refers to the removalof components from a sample. For example, yeast cell walls or yeast cellwall extracts are purified by removal of non-yeast cell wall components(e.g., plasmic membrane and/or yeast intracellular components); they arealso purified by the removal of contaminants or other agents that arenot yeast cell wall. The removal of non-yeast cell wall componentsand/or non-yeast cell wall contaminants results in an increase in thepercent of yeast cell wall or components thereof in a sample. In anotherexample, yeast cell walls comprising clay or clay componentsintegrated/interlaced into the yeast cell wall are purified by theremoval of non-yeast cell wall components (e.g., plasmic membrane and/oryeast intracellular components), thereby the percent of yeast cell wallcomprising clay or clay components integrated/interlaced into the cellwall is increased in a sample.

As used herein, the term “concentrated yeast cell wall extract” refersto yeast cell wall extract that is concentrated via one or moreprocedures (e.g., by drying (e.g., during a drying and concentratingstage)). In another example, a concentrated yeast cell wall extract is ayeast cell wall preparation or yeast cell wall extract preparation thatis purified by removal of non-yeast cell wall components.

As used herein, the terms “modified yeast” and “altered yeast” refer toyeast cultivated in a way that alters the composition, structure and/orfunction of the yeast (e.g., that alters the composition, structureand/or function of the yeast cell wall (e.g., a yeast cell wallcomprising an altered glucan:mannan ratio and/or clay/clay componentintegrated/interlaced into the yeast cell wall that functionsdifferently than a yeast cell wall without altered glucan:mannan ratioand/or non-clay or non-clay component integrated/interlaced yeast cellwall).

As used herein, the term “modified yeast cell wall” refers to yeast cellwall of modified or altered yeast.

As used herein, the term “modified yeast cell wall extract” refers toyeast cell wall extract of modified or altered yeast.

As used herein, the term “concentrated modified yeast cell wall extract”as used herein refers to concentrated yeast cell wall extract derivedfrom modified or altered yeast, for example, in U.S. Pat. No. 6,045,834.

As used herein, the terms “clay interlaced yeast,” “clay integratedyeast,” “clay component interlaced yeast,” “clay component integratedyeast” refer to yeast grown or cultivated in the presence of clay orclay components that has incorporated or interlaced clay or claycomponents into the yeast cell wall. Clay or clay component interlacedyeast and is a specific type of modified yeast.

As used herein, the term “interlaced” as in “clay interlaced yeast cellwall extract,” clay component interlaced yeast cell wall extract,” orthe like refers to the integration of clay or clay component into yeastcell wall. Although a mechanism is not necessary to practice theinvention and the invention is not limited to any particular mechanismof action, in some embodiments, interlacing of clay or clay componentinto yeast cell wall occurs during yeast growth (e.g., after its asexualreproductive cycle (budding) (e.g., as a daughter cell grows and formsits yeast cell wall network, clay or clay component integrates into theyeast cell)). In one example, elongation of the chains of glucan and/orchitin provide integration site(s) involved in the integration of theclay or clay component during budding, resulting in the daughter cellcomprising clay or clay component integrated into its cell wall. Inanother example, the macromolecular clay structure traps yeast cell(s)in its lamellar network, wherein the yeast cell proceeds throughbudding, further integrating clay or clay component into the yeast cellwall. Yeast cell wall integrated/interlaced clay and/or claycomponent(s) remain integrated/interlaced in yeast cell wall post cellwall extraction.

As used herein, the terms “clay interlaced yeast cell wall,” “claycomponent integrated yeast cell wall,” “clay component interlaced yeastcell wall,” and “clay integrated yeast cell wall” refer to yeast cellwall of yeast grown or cultivated in the presence of clay that hasincorporated or interlaced clay or clay components into the yeast cellwall.

As used herein, the terms “clay interlaced yeast cell wall extract,”“clay component interlaced yeast cell wall extract,” “clay integratedyeast cell wall extract,” and “clay component integrated yeast cell wallextract” refer to yeast cell wall extract of yeast (e.g., wherein theyeast from which the cell wall extract is made are grown or cultivatedin the presence of clay) that has incorporated or interlaced clay orclay components into the yeast cell wall (also abbreviated CIYCW).

As used herein, the terms “concentrated interlaced yeast cell wallextract” and “concentrated integrated yeast cell wall extract” refer toconcentrated yeast cell wall extract of yeast grown or cultivated in thepresence of clay that has incorporated or interlaced clay or claycomponents into the yeast cell wall.

As used herein, the term “in vivo” refers to studies and/or experimentsconducted within a living organism, occurring within a biologicalorganism.

As used herein, the term “in vitro” refers to an artificial environmentoutside the living organism and to biological processes or reactionsthat would normally occur within an organism but are made to occur in anartificial environment. In vitro environments can comprise of, but arenot limited to, test tubes and cell culture.

As used herein, the term “high-performance liquid chromatography” andthe term “HPLC” refer to a form of liquid chromatography to separatecompounds. The compounds are dissolved in solution. Compounds areseparated by injecting a plug of the sample mixture onto the column.HPLC instruments comprise a reservoir of mobile phase, a pump, aninjector, a separation column, and a detector. The presence of analytesin the column effluent is recorded by quantitatively detecting a changein refractive index, UV-VIS absorption at a set wavelength, fluorescenceafter excitation with a suitable wavelength, or electrochemicalresponse.

As used herein, the term “scanning electron microscopy” and the term“SEM” refer to a type of electron microscope that images the samplesurface by scanning it with a high-energy beam of electrons in a rasterscan pattern. The electrons interact with the atoms that make up thesample producing signals that contain information about the sample'ssurface topography, composition and other properties such as electricalconductivity.

As used herein, the term “fixation agent” refers to a chemical that iscapable of fixing one substance to another in order to “fix”, stabilize,or otherwise preserve the substance in its current form to prevent thesubstance from degrading or otherwise changing. Often, fixation agentsare used in scanning electron microscopy (abbreviated as SEM) to preparethe sample. Primary fixation agent: as used herein, the terms “primaryfixation agent” refers to the first fixation agent used to “fix” asubstance. Secondary fixation agent: as used herein, the terms“secondary fixation agent” refers to the second fixation agent used to“fix” a substance. Tertiary fixation agent: as used herein, the terms“tertiary fixation agent” refers to the third fixation agent used to“fix” a substance.

As used herein, the term “analyte” refers to an atom, a molecule, agrouping of atoms and/or molecules, a substance, or chemicalconstituent. An analyte, in and of itself cannot be measured, rather,aspects or properties (physical, chemical, biological, etc.) of theanalyte can be determined using an analytical procedure, such as HPLC.For example, one cannot measure a “chair” (analyte-component) in and ofitself, but, the height, width, etc. of a chair can be measured.Likewise, one cannot measure a mycotoxin but can measure the mycotoxinfluorescence that is related to its concentration.

As used herein, the term “signal” is used generally in reference to anydetectable process that indicates that a reaction has occurred (forexample, binding of antibody to antigen). Signals can be assessedqualitatively as well as quantitatively. Examples of types of “signals”include, but are not limited to, radioactive signals, fluorimetricsignals or colorimetric product/reagent signals.

As used herein, the term “bioavailability” refers to the fraction of amolecule or component that is available to an organism or reaches thesystemic circulation. When a molecule or component is administeredintravenously, its bioavailability is 100%. However, when a molecule orcomponent is administered via other routes (such as orally), itsbioavailability decreases (due to incomplete absorption and first-passmetabolism).

As used herein, the term “absorb” refers to the process by which amaterial “takes in” or “sucks up” another substance. For example,“absorption” may refer to the process of absorbing or assimilatingsubstances into cells or across the tissues and organs through diffusionor osmosis (e.g. absorption of nutrients by the digestive system orabsorption of drugs into the blood stream).

As used herein, the term “adsorption” refers to a process that occurswhen a material is sequestered by, and/or accumulates on the surface of,a solid or a liquid (sequestrant and/or adsorbent) (e.g. thereby forminga film of molecules or atoms (the adsorbate)).

As used herein, the term “sequester” and/or the term “sequestration”refers to physical association (e.g., via docking or encasement) of twoor more entities that come into contact with one another (e.g., therebyforming a stable complex). Exemplary forms of associations include, butare not limited to, hydrogen bonding, coordination, and ion pairformation. Sequestration interactions may involve a variable number ofchemical interactions (e.g., chemical bonds) depending on thestereochemistry and geometry of each entity (e.g., further defining thespecificity of the sequestration). When two or more entities aresequestered they may be sequestered by way of chemical bonds, but mayalso be associated via charge or other type of interactions.

As used herein, the term “sequestration agent” and/or “sequesteringagent”, refers to an entity that is capable of inducing or otherwisebeing involved with a sequestration and/or forming a complex with asecond entity.

As used herein, the term “sorption” refers to both adsorption andabsorption.

As used herein, the term “effective amount” refers to the amount of acomposition (e.g., comprising a yeast cell, yeast cell wall or modifiedyeast cell wall component of the invention) sufficient to effectbeneficial or desired results. An effective amount can be administeredand/or combined with another material in one or more administrations,applications or dosages and is not intended to be limited to aparticular formulation or administration route.

As used herein, the term “digest” refers to the conversion of food,feedstuffs, or other organic compounds into absorbable form; to soften,decompose, or break down by heat and moisture or chemical action.

As used herein, “digestive system” refers to a system (includinggastrointestinal system) in which digestion can or does occur.

As used herein, the term “feedstuffs” refers to material(s) that areconsumed by animals and contribute energy and/or nutrients to ananimal's diet. Examples of feedstuffs include, but are not limited to,Total Mixed Ration (TMR), forage(s), pellet(s), concentrate(s),premix(es) coproduct(s), grain(s), distiller grain(s), molasses,fiber(s), fodder(s), grass(es), hay, kernel(s), leaves, meal,soluble(s), and supplement(s).

As used herein, the term “animal” refers to those of kingdom Animalia.This includes, but is not limited to livestock, farm animals, domesticanimals, pet animals, marine and freshwater animals, and wild animals.

As used herein, the terms “administration” and the term “administering”refer to the act of giving a substance, including a drug, prodrug, orother agent, or therapeutic treatment to a subject (e.g., a subject orin vivo, in vitro, or ex vivo cells, tissues, and organs). Exemplaryroutes of administration can be through the eyes (ophthalmic), mouth(oral), skin (topical or transdermal), nose (nasal), lungs (inhalant),oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g.,intravenously, subcutaneously, intratumorally, intraperitoneally, etc.)and the like.

As used herein, the term “co-administration” and the term“co-administering” refer to the administration of at least two agent(s)or therapies to a subject and/or material (e.g., feedstuff).Co-administration of two or more agents or therapies can be concurrent,or a first agent/therapy can be administered prior to a secondagent/therapy.

As used herein, the term “treatment” refers to the improvement and/orreversal of the symptoms of disease (e.g., mycotoxicosis). The term“treatment” refers to both therapeutic treatment and prophylactic orpreventative measures. For example, subjects that may benefit fromtreatment with compositions and methods of the present invention includethose already with a disease and/or disorder (e.g., mycotoxicosis) aswell as those in which a disease and/or disorder is to be prevented(e.g., using a prophylactic treatment of the present invention).

As used herein, the term “at risk for disease” refers to a subject thatis predisposed to experiencing a particular disease. This predispositionmay be genetic (e.g., a particular genetic tendency to experience thedisease, such as heritable disorders), or due to other factors (e.g.,age, weight, environmental conditions, exposures to detrimentalcompounds present in the environment, etc.).

As used herein, the term “disease”, the term “infection” and the term“pathological condition or response” refer to a state, signs, and/orsymptoms that are associated with an impairment of the normal state of aliving animal or of any of its organs or tissues that interrupts ormodifies the performance of normal functions, and may be a response toenvironmental factors (such as malnutrition, industrial hazards, orclimate, including mycotoxicosis), specific infective agents (such asworms, bacteria, or viruses), to inherent defect of the organism (suchas various genetic anomalies), or combinations of these and otherfactors.

As used herein, the term “mycotoxicosis” refers to a condition in whichmycotoxins pass the resistance barriers of the human or animal body.Mycotoxicosis can be considered either an infection or a disease and mayhave a deleterious effect on those afflicted.

As used herein, the term “mycotoxin” refers to toxic and/or carcinogeniccompound(s) produced by various fungal species.

As used herein, the term “suffering from disease” refers to a subject(e.g., an animal or human subject) that is experiencing a particulardisease and is not limited to any particular signs or symptoms, ordisease.

As used herein, the term “toxic” refers to any detrimental, deleterious,harmful, or otherwise negative effect(s) on a subject, a cell, or atissue as compared to the same cell or tissue prior to the contact oradministration of the toxin/toxicant.

As used herein, the term “acid” as used herein refers to any chemicalcompound that can donate proton(s) and/or accept electron(s). Acidsinclude, but are not limited to, hydrochloric, hydrobromic, sulfuric,nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic,salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric,methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic,naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids,such as oxalic, while not in themselves pharmaceutically acceptable, maybe employed in the preparation of salts useful as intermediates inobtaining the compounds of the invention and their pharmaceuticallyacceptable acid addition salts.

As used herein, the term “base” refers to any chemical compound that canaccept proton(s) and/or donate electron(s) or hydroxide ions. Basesinclude, but are not limited to, alkali metal (e.g., sodium) hydroxides,alkaline earth metal (e.g., magnesium) hydroxides, ammonia, andcompounds of formula NW₄ ⁺, wherein W is C₁₋₄ alkyl, and the like.

As used herein, the term “salt” refers to compounds that may be derivedfrom inorganic or organic acids and bases. Examples of salts include,but are not limited to, acetate, adipate, alginate, aspartate, benzoate,benzenesulfonate, bisulfate, butyrate, citrate, camphorate,camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate,ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate,hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide,2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate,2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate,persulfate, phenylpropionate, picrate, pivalate, propionate, succinate,tartrate, thiocyanate, tosylate, undecanoate, and the like. Otherexamples of salts include anions of the compounds of the presentinvention compounded with a suitable cation such as Na⁺, NH₄ ⁺, and NW₄⁺ (wherein W is a C₁₋₄ alkyl group), and the like.

As used herein, the term “pharmaceutical composition” refers to thecombination of an active agent (e.g., a composition comprising a viableyeast cell, yeast cell wall, or modified yeast cell wall component ofthe invention) with a carrier, inert or active, making the compositionespecially suitable for diagnostic or therapeutic use in vitro, in vivoor ex vivo.

As used herein, the term “pharmaceutically acceptable” and the term“pharmacologically acceptable” refer to compositions that do notsubstantially produce more known adverse reactions than known beneficialreactions.

As used herein, the term “antifoaming agent” refers to an additive usedto prevent formation of foam or is added to break foam already formed.An “antifoaming agent” also referred to as “antifoamer” or “defoamer”refers to an additive which reduces the surface tension of a solution ormedia or emulsion or broth in fermenters because of aeration oragitation, thus inhibiting or modifying the formation of a foam.Commonly used agents are insoluble oils, dimethyl polysiloxanes andother silicones, certain alcohols such as stearyldecanol, octal decanol,sulphonates, stearates and glycols.

As used herein, the term “cell” refers to an autonomous self-replicatingunit that may exist as functional independent unit of life (as in thecase of unicellular organism, e.g. yeast), or as sub-unit in amulticellular organism (such as in plants and animals) that isspecialized into carrying out particular functions towards the cause ofthe organism as a whole. There are two distinct types of cells:prokaryotic cells and eukaryotic cells.

As used herein, the term “eukaryote” refers to organisms whose cells areorganized into complex structures enclosed within membranes.“Eukaryotes” are distinguishable from “prokaryotes.” The term“prokaryote” refers to organisms that lack a cell nucleus or othermembrane-bound organelles. The term “eukaryote” refers to all organismswith cells that exhibit the typical characteristics of eukaryotes, suchas the presence of a true nucleus bounded by a nuclear membrane, withinwhich lie the chromosomes, the presence of membrane-bound organelles,and other characteristics commonly observed in eukaryotic organisms.Thus, the term includes, but is not limited to such organisms as fungi,protozoa, and animals.

As used herein, the term “cell culture” refers to any in vitro cultureof cells. Included within this term are continuous cell lines (e.g.,with an immortal phenotype), primary cell cultures, transformed celllines, finite cell lines (e.g., non-transformed cells), and any othercell population maintained in vitro.

As used herein, the term “cell reproduction” refers to a process of cellmultiplication having three primary stages. The first stage of cellreproduction involves the replication of the “parental cell's DNA. Thesecond stage is the separation of the duplicated DNA into two equallysized groups of chromosomes. The third stage is the physical division ofentire cells, usually called cytokinesis. Cell reproduction is morecomplex in eukaryotes than in other organisms. Non-eukaryotic cells suchas bacterial cells reproduce by binary fission, a process that includesDNA replication, chromosome segregation, and cytokinesis. Eukaryoticcell reproduction either involves mitosis or a more complex processcalled meiosis. Mitosis and meiosis are sometimes called the two“nuclear division” processes. Binary fission is similar to eukaryoticcell reproduction that involves mitosis. Both lead to the production oftwo daughter cells with the same number of chromosomes as the parentalcell. Meiosis is used for a special cell reproduction process of diploidorganisms. It produces four special “daughter cells” (gametes) whichhave half the normal cellular amount of DNA. A male and a female gametecan then combine to produce a zygote, a cell which again has the normalamount of chromosomes.

As used herein, the term “yeast reproduction” refers to the reproductioncycle of yeast, which have asexual and sexual reproductive cycles,however the most common mode of vegetative growth in yeast is asexualreproduction by “budding” or “fission” with a “daughter cell” that isformed on the “parent cell”. The nucleus of the parent cell splits intoa daughter nucleus and migrates into the daughter cell. The budcontinues to grow until it separates from the “parent cell”, forming anew cell. Under high stress conditions haploid cells will generally die,however under the same conditions diploid cells can undergo sporulation,entering sexual reproduction (meiosis) and producing a variety ofhaploid spores, which can go on to mate (conjugate), reforming thediploid.

As used herein, the term “budding” refers to a type of cell division infungi (e.g. yeast) and in protozoa in which one of the “daughter cells”develops as a smaller protrusion from the other. Usually the position ofthe budding cell is defined by polarity in the “parent cell”. In someprotozoa the budded daughter may lie within the cytoplasm of the otherdaughter.

As used herein, the term “daughter cell” refers to one of the two ormore cells formed in the division of a parent cell.

As used herein, the term “parent cell” and the term “mother cell” referto the cell giving rise to daughter cells by cell division.

As used herein, the term “inoculation” refers to the act of introducinga microorganism or suspension of microorganisms (e.g. yeast, fungi,bacteria, etc.) into a culture medium. Inoculation is the act or processof introducing something to where it will grow or reproduce.

As used herein, the term “inoculum” and the term “pre-inoculum” refer tocells used in an inoculation, such as cells added to start a culture.

As used herein, the term “growth procedure” refers to the reproductionof living cells applied to yeast cells where the phrase “cell growth” isshorthand for the idea of “growth in cell numbers by means of cellreproduction.” During cell reproduction one cell (the “parental cell” or“mother cell”) divides to produce “daughter cells”.

As used herein, the term “cultivate yeast” and the term “growing yeast”refer to the act of populating and/or propagating yeast.

As used herein, the term “centrifugation” refers to the separating ofmolecules by size or density using centrifugal forces generated by aspinning rotor that puts an object in rotation around a fixed axis,applying a force perpendicular to the axis. The centrifuge works usingthe sedimentation principle, where the centripetal acceleration is usedto evenly distribute substances of greater and lesser density intodifferent layers of density.

As used herein, the term “concentration” refers to the amount of asubstance per defined space. Concentration usually is expressed in termsof mass per unit of volume. To dilute a solution, one must add moresolvent, or reduce the amount of solute (e.g., by selective evaporation,spray drying, freeze drying, e.g., concentrated yeast cell wall extractor concentrated modified yeast cell wall extract). By contrast, toconcentrate a solution, one must add more solute, or reduce the amountof solvent.

As used herein, the term “layer” refers to a usually horizontal depositorganized in stratum of a material forming an overlying part or segmentobtained after separation by centrifugation in relation with the densityproperties of the material.

As used herein, the term “harvest” refers to the act of collecting orbringing together materials that have been produced (e.g. bringingtogether materials produced during yeast production).

As used herein, the term “clay” refers to mineral clays, synthetic,organoclays and any mixture(s) thereof.

As used herein, the term “mineral clay” refers to a naturally occurringor synthetic material composed primarily of fine-grained minerals(silicates) that show plasticity through a variable range of watercontent (which may be a result of water trapped in the structure bypolar attraction) and can be hardened when dried and/or fired. Examplesof silicates include, but are not limited to, phyllosilicate, bentonite,zeolite, aluminosilicate, montmorillonite, smectite, kaolinite.

As used herein, the term “organoclay” and the term “modified clay” referto an organically modified phyllosilicate, derived from a naturallyoccurring clay mineral. By exchanging the original interlayer cationsfor organocations (typically quaternary alkylammonium ions) orpolysaccharides, an organophilic surface is generated, consisting ofcovalently linked organic moieties. The lamellar structure remainsanalogous to the parent phyllosilicate.

As used herein, the term “drying” refers to spray drying, freeze drying,air drying, vacuum drying or any other kind of process that reduces oreliminates liquid in a substance.

As used herein, the term “spray drying” refers to a commonly used methodof drying a substance containing liquid using hot gas to evaporate theliquid to reduce or eliminate liquid in the substance. In other wordsthe material is dried by way of spraying or atomizing into a draft ofheated dry air.

As used herein, the term “freeze-drying” and the term “lyophilization”and the term “cryodesiccation” refer to the removal of a solvent frommatter in a frozen state by sublimation.

This is accomplished by freezing the material to be dried below itseutectic point and then providing the latent heat of sublimation.Precise control of heat input permits drying from the frozen statewithout product melt-back. In practical application, the process isaccelerated and precisely controlled under reduced pressure conditions.

As used herein, the term “dry free flowing powder” refers to a freeflowing dry powder.

As used herein, the term “grinding” refers to reducing particle size byimpact, shearing, or attrition.

As used herein, the term “washing” refers to the removal or cleansing(e.g., using any type of solute (e.g. distilled water, buffer, orsolvent) or mixture) of impurities or soluble unwanted component of apreparation (e.g., a yeast cell wall extract may be washed to removenon-yeast cell wall components from the sample).

As used herein, the term “enzyme” refers to as a protein orprotein-based molecule with a characteristic sequence of amino acidsthat fold to produce a specific three-dimensional structure which givesthe molecule unique properties and that acts as a catalyst or a chemicalfor specific chemical reactions, converting a specific set of reactants(called substrates) into specific products.

As used herein, the term “peptide,” the term “polypeptide” and the term“protein” refer to a primary sequence of amino acids that are joined bycovalent “peptide linkages.” Generally, a peptide consists of a fewamino acids, typically from 2-50 amino acids, and is shorter than aprotein. The term “polypeptide” encompasses peptides and proteins.Peptides, polypeptides or proteins can be synthetic, recombinants ornaturally occurring. A synthetic peptide is produced by artificial meansin vitro (e.g., was not produced in vivo).

As used herein, the term “proteases” refers to any of various enzymes,including the endopeptidases and exopeptidases that catalyze thehydrolytic breakdown of proteins into peptides or amino acids.

As used herein, the term “lysis” refers to the disintegration or ruptureof the yeast cell membrane and yeast cell wall resulting in the releaseof the intracellular components. As used herein, “lysis” occurs as aresult of physical/mechanical, enzymatic (including autolysis andhydrolysis) or osmotic mechanisms (including “alcohol shocking” andhydrolysis).

As used herein, the term “autolysis” refers to the breakdown of a partor whole cell or tissue by self-produced enzymes.

As used herein, the term “hydrolysis”, refers to the process ofsplitting a compound into fragments with the addition of water (e.g.,that is used to break down polymers into simpler units (e.g. starch intoglucose)).

As used herein, “alcohol shocking” refers to an osmotic stress generatedby the addition of an alcohol (e.g. ethanol) to growth medium to createa difference between the osmotic pressure of the medium and the osmoticpressure inside cells (e.g., yeast cells) growing in the medium. Alcoholshocking may lead to the lysis of cells (e.g., yeast cells) grown in themedium.

As used herein, the term “osmosis” refers to the diffusion of a solvent(e.g., water) through a semi-permeable membrane, from a solution of lowsolute concentration (high water potential) to a solution with highsolute concentration (low water potential), up a solute concentrationgradient. It is a physical process in which a solvent moves, withoutinput of energy, across a semi-permeable membrane (permeable to thesolvent, but not the solute) separating two solutions of differentconcentrations. Net movement of solvent is from the less-concentrated(hypotonic) to the more-concentrated (hypertonic) solution, which tendsto reduce the difference in concentrations.

As used herein, the term “osmotic stress” and the term “osmotic shock”refer to a sudden change in the solute concentration around a cell,causing a rapid change in the movement of water across its cellmembrane. Under conditions of high concentrations of either salts,substrates or any solute in the supernatant water is drawn out of thecells through osmosis. This also inhibits the transport of substratesand cofactors into the cell thus “shocking” the cell. Alternatively, atlow concentrations of solutes, water enters the cell in large amounts,causing it to swell and either burst or undergo apoptosis.

As used herein, the term “sample” is used in a broad sense including aspecimen or culture obtained from any source, as well as biological andenvironmental samples. Biological samples may be obtained from animals(including humans) and encompass fluids, solids, tissues, and gases.Biological samples include blood products, such as plasma, serum and thelike. Environmental samples include environmental material such assurface matter, soil, water, crystals and industrial samples.

As used herein, the term “complex” refers to an entity formed byassociation between two or more separate entities (e.g., associationbetween two or more entities wherein the entities are the same ordifferent (e.g., same or different chemical species). The associationmay be via a covalent bond or a non-covalent bond (e.g., via van derWaals, electrostatic, charge interaction, hydrophobic interaction,dipole interaction, and/or hydrogen bonding forces (e.g., urethanelinkages, amide linkages, ester linkages, and combination thereof)).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel yeast cells comprising a cell wallstructure that has been modified (e.g., clay and/or clay components areinterlaced into the yeast cell wall and/or the glucan:mannan ratio hasbeen altered), methods of producing the same, compositions comprisingand/or derived from the same, and methods of using the same (e.g., tosequester bacteria and mycotoxins).

In some embodiments, the present invention provides a yeast cell wallextract (e.g., an isolated, purified, modified and/or concentrated cellwall extract) comprising clay and/or clay component(s) interlaced intothe cell wall (e.g., due to cultivation of the yeast cell in thepresence of a clay) and/or yeast cell wall extract comprising alteredglucan:mannan structure. In some embodiments, the clay interlaced yeastcell wall extract comprising clay and/or clay component interlaced intothe yeast cell wall and/or yeast cell wall extract comprising alteredglucan:mannan structure is admixed or otherwise added to feedstuffs,organic matter (e.g., bedding), and/or water thereby sequesteringmycotoxins (e.g., while in the gastrointestinal tract of the animal orduring filtration), and negating or reducing the negative effects ofmycotoxins. Thus, in some embodiments, the present invention providesmethods that significantly improve the adsorptive/sequesteringproperties of yeast cell wall-based material toward mycotoxins (e.g.,that significantly adsorb and/or sequester and/or limit thebioavailability of a variety of mycotoxins (e.g., not adsorbed to and/ornot sequestered using clay alone, yeast cell wall extract alone, acombination of yeast cell wall extract to which a clay is later added ona dry blend basis; and/or a chemical grafting of polysaccharidematerials on top of clay based products) in the digestive tract of ananimal).

In some embodiments, the present invention provides a novel preparationof yeast cells grown in the presence of one or more clays. In someembodiments, clay interlaced yeast cell walls are extracted from theclay interlaced yeast cells grown in the presence of one or more clays.In some embodiments, the clay interlaced yeast cell wall extract ispurified and/or concentrated. As described herein, the present inventionis not limited to any particular yeast cell strain or to any particularclay. In some embodiments, the clay source is a standard commercialgrade clay source (e.g., selected for exhibiting in vitro, in vivo,and/or ex vivo properties toward mycotoxins, or a clay source selectedbecause it does not exhibit in vitro, in vivo, and/or ex vivo propertiestoward mycotoxins). Compositions and methods of the present inventioncan be utilized for adsorbing and/or sequestering of mycotoxins in avariety of subjects. Indeed, the present invention is not limited by thetype of subject that benefits from the compositions and methodsdescribed herein. The present invention can benefit all animals,however, exemplary subjects include, but are not limited to, humans,avian, bovine, porcine, equine, ovine, caprine, canine, feline, piscine,camelid, rodent species as well as fish and shellfish subjects. In someembodiments, when admixed with organic matter (e.g., including beddingand feedstuffs), and/or water, and/or fed directly to a subject,compositions of the present invention decrease the absorption or uptakeof mycotoxins by the subject, thereby alleviating reduced performance,health and/or reducing the incidence mycotoxin-associated diseases andpathological responses in the subject.

In some embodiments, the present invention provides a method for makingand/or generating yeast cells comprising clay and/or clay component(s)interlaced into the yeast cell wall, and/or comprising an alteredglucan:mannan structure. For example, in some embodiments, the presentinvention provides a yeast cell generated and/or cultivated in thepresence of a clay wherein the yeast cell wall comprises a glucan:mannanratio that is greater than (e.g., 2.5% greater, 5% greater, 10% greater,15%, 20% greater, 25% greater, 30% greater, 40% greater, 50% greater ormore) the glucan:mannan ratio of yeast cells generated/cultivated in theabsence of a clay (See, e.g., Example 2). In some embodiments, thepresent invention provides a yeast cell wall extract obtained from(e.g., isolated, purified and/or concentrated from) a viable yeast cellgenerated and/or cultivated in the presence of a clay wherein the yeastcell wall comprises a glucan:mannan ratio that is greater (e.g., 2.5%greater, 5% greater, 10% greater, 15%, 20% greater, 25% greater, 30%greater, 40% greater, 50% greater or more) than the glucan:mannan ratioof yeast cells generated/cultivated in the absence of a clay (See, e.g.,Example 2).

Thus, the present invention provides novel, clay interlaced yeast cellwall extract from yeast cultivated in the presence of a clay, andmethods of generating the same. In some embodiments, a method ofgenerating yeast cells comprises cultivating yeast cells including, butnot limited to, Saccharomyces, Candida, Kluyveromyces, and Torulasporaspecies in the presence of one or more clays in order to alter orotherwise modify the yeast cell wall (e.g., in order to enhance theability of the yeast cell wall to adsorb and/or sequester mycotoxins(e.g., due to the yeast cell wall interlaced with clay and/or claycomponent(s) and/or comprising an altered glucan:mannan structure)). Insome embodiments, the present invention provides the blending of one ormore clay based materials including, but not limited to, silicates(e.g., group of tectosilicates (e.g., zeolites, quartz, feldspars);phyllosilicates (e.g., kaolinite, halloysite, dicktite, nacrit,chysotile, antigorite, lizardite, talc), pyrophyllites, smectites (e.g.,montmorillonite, beidellite, nontronite; vermiculites, micasantigorite,muscovite, illite, phengite, biotite); sepiolite, palygorskite,attapulgite), and/or a hydrated aluminum silicate (e.g.,montmorillonites, bentonite)) to a yeast cell culture medium (e.g., asdescribed in Examples 1, 5, and 6). The present invention provides thatthe viable yeast cells incorporate the clay and/or clay components intothe yeast cell wall structure (e.g., as shown in FIGS. 1A and 1B andFIG. 2). In some embodiments, the one or more clays blended into a yeastcell culture medium are present at a concentration of about 0.075%,0.1%, 0.125%, 0.25%, 0.5%, 1%, 2%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%,15%, or more of the total growth medium. In some embodiments, the amountof one or more clays blended into a yeast cell culture medium does notexceed 2% of the final content of a reactor in which the yeast cells aregrown. In some embodiments, an amount of clay added to yeast cellculture medium is chosen that does not lead to swelling of the yeastcell culture medium (e.g., is about 2.0% or less). In some embodiments,the amount of clay added to yeast cell culture medium is chosen thatproduces a yeast cell wall extract harvested from the yeast thatcomprises an amount of clay that has regulatory approval for use as afeed additive in non-medicated animal feed (e.g., does not to exceed 2%in total ration). In some embodiments, a food-grade anti-foaming agentor defoamer is added to the cell culture medium, (e.g., including butnot limited to, nonsilicone molecular defoamers, oil based defoamers(e.g., mineral oil, vegetable oil, white oil, or other oil that isinsoluble in the foaming medium) or silicone compound based defoamers(e.g., delivered as an oil or water based emulsion)). In someembodiments, waxes (e.g., ethylene bis stearamide (EBS), paraffinicwaxes, ester waxes or fatty alcohol waxes) and/or hydrophobic silica areadded to improve emulsification and spreading in the foaming medium.

Experiments conducted during development of embodiments of the inventionidentified a number of factors as important for growth of yeast cells inthe presence of one or more clays. For example, in some embodiments, itis preferred to maintain the (w/v) relationship (e.g., corresponding tograms/cubic centimeter (g/cc)) between the clay support material and thewater at or below 3% (e.g., to avoid reaching a solid or semi-solidstate (e.g., due to water adsorption and retentiveness of the claymaterial)). Thus, water sorption of the water-swellable hydratedaluminum silicate is a limiting factor impacting the ratio of claysupport material to water in the formulation of a culture medium of thepresent invention. In some embodiments, culture media and bottles usedare sterilized, and inoculation with microorganisms is effected inaccordance with standard procedures. For example, in some embodiments, apre-inoculum is prepared with active dry yeast in a bottle of steriledeionized water and incubated at about 25-30° C. (e.g., 28° C.) for aset period of time (e.g., 20 min). In some embodiments, inoculation ofthe pre-inoculum is aseptically performed (e.g., at a temperature ofabout 30° C.). In some embodiments, pH and glucose levels are monitoredand maintained. In some embodiments, agitation of the culture isincreased incrementally (e.g., from 100 to 500 rpm) during growth. Insome embodiments, one or more clays are added aseptically to the cultureduring growth (e.g., when less than half, about half, or more than halfof the culture nutrients are consumed).

In some embodiments, as the amount of clay blended into the yeast cellculture medium increases (e.g., in an amount dependent upon the type ofclay or clays used) the swelling properties of the clay materialinhibits yeast cell growth.

In some embodiments, growing yeast in clay-blended yeast cell culturemedium provides conditions which stress the growing yeast. Although thepresent invention is not limited to any particular mechanism of action,and an understanding of the mechanism of action is not necessary topractice the present invention, in some embodiments, the stress appliedto the yeast by the clay-blended cell-culture medium causes yeast toproduce more glucan, resulting in increased ratios of glucan:mannan.

In some embodiments, the present invention provides that yeast cellscultivated in the presence of one or more clays not only interlaces theclay and/or a component of the clay into the yeast cell wall, but alsodisplay an altered cell wall composition (e.g., characterized by alteredratios of glucan:mannan, total protein content, and/or remnant amounts).For example, the present invention provides yeast cells comprising aglucan:mannan ratio that is greater (e.g., 2.5% greater, 5% greater, 10%greater, 15%, 20% greater, 25% greater, 30% greater, 40% greater, 50%greater or more) than the glucan:mannan ratio of the yeast cellscultivated in the absence of clay (See, e.g., Example 2). The presentinvention also provides yeast cells and yeast cell wall extractscomprising an enhanced total protein content (e.g., 100%, 200%, 300%,400%, 500% or more enhance protein content) compared to the totalprotein content of yeast cells and/or yeast cell wall extracts generatedin the absence of a clay (See, e.g., Example 2).

In some embodiments, the present invention provides yeast cell wallextracts comprising clay and/or clay component(s) interlaced into theyeast cell wall and/or comprising an altered glucan:mannan ratio of thestructure, that provides superior mycotoxin sequestration propertiesthan conventional compositions. The present invention is not limited byany particular method of generating a yeast cell wall extract from yeastcultivated in the presence of one or more clays. Indeed, a variety ofprocedures may be utilized to generate yeast cell wall extractsincluding, but not limited to, use of glass beads and a bead beater,enzymatic (e.g., protease (e.g., papain)) treatment, mechanical lysis,autolysis and hydrolysis, and other methods known in the art (See, e.g.,Peppler, H. J. 1979. Production of yeasts and yeast products. Page 157in: Microbial Technology & Microbial Processes, Vol. 1 (2d Ed.),Academic Press). Following lysis and extraction, clay and/or claycomponent interlaced/integrated yeast cell wall is washed to removeintracellular components and to purify and concentrate the extract. Theresulting extract may be dried by any of a number of methods common inthe art including, but not limited, freeze-drying and/or spray-drying(e.g., to form a hygroscopic water-insoluble powder).

Accordingly, the invention provides, in some embodiments, yeast cellwall extract comprising clay and/or clay component interlaced directlyinto the yeast cell wall. In some embodiments, a composition comprisinga yeast cell wall extract of the invention comprising clay and/or claycomponents integrated directly into the yeast cell wall comprises lessthan about 0.5% clay, 0.5-1%, 1-2%, 2-5%, 5-10%, 10-15%, 15-20%, 20-30%,30-40%, 40-50%, 50-60%, 60-70%, 70% or more clay and/or clay componentas part of a yeast cell wall extract (on a w/w % basis). In someembodiments, increasing the amount of clay in a culture medium increasesthe amount of clay and/or clay component content of a yeast cell wallextract.

In some embodiments, clay that is added to yeast cell growth medium thatis not incorporated into a yeast cell is collected and utilized in asubsequent yeast cell growth procedure (e.g., the unincorporated claymaterial is recycled). For example, recycling of clay material isfacilitated by the sedimentation properties of the clay compared toyeast. Indeed, experiments conducted during development of embodimentsof the invention have produced two recoverable layers, (i) a bottomlayer containing clay material only (at 99%); and (ii) a top layercontaining a clay fraction incorporated into yeast. Thus, although amechanism is not necessary to practice the present invention and thepresent invention is not limited to any particular mechanism of action,in some embodiments, the present invention provides a direct inclusionof clay particles into and/or onto the yeast cell wall (e.g., thatsurvives yeast cell wall extract preparation processes (e.g., via directinterlacing of clay or clay component into the glucan polymer chains ofthe yeast cell wall)). In other embodiments, a clay fraction traps ayeast cell during culture and upon budding, together with daughtercells, the yeast cells are encaged in a clay comprising macrostructurebefore the yeast is lysed and its intracellular components removed bywashing. In some embodiments, glucan chains grow in between the lamellarstructure of the clay.

In some embodiments, a yeast cell or yeast cell wall component (e.g., ayeast cell wall extract generated and isolated as described herein(e.g., comprising clay or clay component interlaced into the yeast cellwall and/or comprising an altered glucan and/or mannan structure)) iscombined with one or more other agents including, but not limited to, anenzyme (e.g., esterase, epoxidase), a bacteria, a yeast or yeastcomponent, clay, etc. (e.g., prior to admixing with feeds, incorporatinginto pelleted feeds, and/or feeding to animals)).

In some embodiments, the present invention utilizes yeast cellscomprising altered yeast cell wall structure (e.g., clay and/or claycomponent interlaced into the yeast cell walls and/or cell wallscomprising altered glucan and/or mannan structure), compositionscomprising the same, and/or compositions derived from the same, that areutilized with one or more methods and/or materials described herein foruse in compositions and/or methods for the reduction, removal and/orelimination of mycotoxins (e.g., physical, mixing, chemical,microbiological methods described herein (e.g., to adsorb and/orsequester bacteria and toxins)). For example, in some embodiments, ayeast cell or yeast cell wall component (e.g., a yeast cell wall extractproduced as described herein (e.g., comprising clay or clay component(s)interlaced into the yeast cell wall and/or comprising an altered glucanand/or mannan structure)) is utilized with one or more physical, mixing,chemical, or microbiological methods described herein to sequestermycotoxins.

The present invention is not limited by the type of mycotoxinsequestered. Indeed, compositions of the present invention (e.g., clayinterlaced yeast cell wall extracts) can be utilized to adsorb and/orsequester a variety of mycotoxins including, but not limited to,acetoxyscirpenediol, acetyldeoxynivalenol, acetylnivalenol,acetylneosolaniol, acetyl T-2 toxin, extended to all aflatoxins,aflatoxin B1, B2, G1 and G2, aflatrem, altenuic acid, alternariol,austdiol, austamide, austocystin, avenacein+1, beauvericin+2,bentenolide, brevianamide, butenolide, calonectrin, chaetoglobosin,chaetocin, chaetomin, citrinin, citreoviridin, cochliodinol,cytochalasins, cyclopiazonic acid, deacetylcalonectrin,deactylneosolaniol, deoxynivalenol diacetate, deoxynivalenolmonoacetate, diacetoxyscirpenol, destruxin B, emestrin, enniatins,extended to all ergot alkaloids toxins and endophytes such as ergine,ergocornine, ergocristine, ergocryptine, ergometrine, ergonine,ergosine, ergotamine, ergovaline, lysergol, lysergic acid, and relatedepimers, fructigenin+1, fumagilin, fumonisins, fumonisins A1, A2, B1 andB2 and B3, fusarenon-X, fusarochromanone, fusaric acid, fusarin,gliotoxin, HT-2 toxin, hyalodendrin, ipomeanine, islanditoxin,isofumigaclavines A and B, lateritin+1, leptosin, lycomarasmin+1,malformin, maltoryzine, moniliformin, monoacetoxyscirpenol, mycophenolicacid, neosolaniol, nivalenol, NT-1 toxin, NT-2 toxin, extended to allochratoxins, oosporein, oxalic acid, paspalitrem A and B, patulin,penicillic acid, penitrem, phomopsins, PR-toxin, roridin E, roquefortineA and B, rubratoxin, rubroskyrin, rubrosulphin, rugulosin, sambucynin+1,satratoxins, F, G, H, scirpentriol, sirodesmin, slaframine, sporidesmin,sterigmatocystin, swainsonine, T-1 toxin, T-2 toxin, tenuazoic acid,triacetoxyscirpendiol extended to all trichothecenes, trichodermin,trichothecin, trichoverrins, trichoverrols, tryptoquivalene, verrucarin,verruculogen, verticillins, viopurpurin, viomellein, viriditoxin,wortmannin, xanthocillin, yavanicin+1, zearalenols, zearalanones,zearalenone, α, β, zearalanone, α, β, zeranol and subfamilies and/orderivatives of the same, and/or conjugates. In some embodiments,compositions and methods of the invention are utilized to adsorb and/orsequester aflatoxins, zearalenone, ochratoxins, trichothecene,fumonisin, patulin, and/or endophyte related ergot and possibleconjugates and metabolites of the aforementioned mycotoxins. Experimentsconducted during development of the invention demonstrate the benefit(s)of using the present invention compared to historical or conventionalmethods. For example, as described herein, a drawback of using acomposition comprising only (1) a clay, (2) a composition comprisingonly a yeast cell wall extract, as well as (3) a composition comprisinga yeast cell wall extract to which a clay has been added, is that suchcompositions and methods of using the same are less effective means thanthe present invention for reducing the negative effects of mycotoxinsand have more drawbacks. However, clay interlaced yeast cell wallextracts of the present invention (e.g., comprising clay and/or claycomponent interlaced into the yeast cell wall, and/or comprising analtered glucan and/or mannan structure) display the unexpected abilityto sequester a variety of mycotoxins, and also display a strikinglyenhanced ability to adsorb mycotoxins compared to conventionalcompositions (e.g., a composition comprising only clay(s), a compositioncomprising only a yeast cell wall extract, as well as a compositioncomprising a yeast cell wall extract to which clay(s) has been added,See Examples 2-3). Thus, the present invention provides compositions andmethods that display unexpected and superior sequestration and/oradsorption properties with respect to a variety of mycotoxins not foundin conventional compositions and methods. Thus, the present inventionprovides clay interlaced yeast cell wall-based materials and methods ofmaking and using the same to provide an efficient method to sequestermycotoxins in the digestive tract of animals and humans (e.g., viaadsorbing mycotoxins present in feedstuffs, other organic matter and/orwater) while also providing lower or no adsorption of beneficialnutrients and lesser or no negative effects on the environment.

In some embodiments, a preferred physical form of the invention is a dryfree-flowing powder suitable for direct inclusion into feedstuffs, otherorganic matter (e.g., bedding) or as a direct supplement to an animal.

Compositions of the invention can be added to any organic matter (e.g.,bedding, feedstuff for animals, feedstuff for humans) and/or water(e.g., water used for animal and/or human consumption, environmentalwater (e.g., ponds, lakes, reservoirs, fish tanks, etc.)) to removemycotoxins from the matter. When incorporated directly into animalfeedstuffs, a composition of the invention is added in amounts rangingfrom about 0.0125% to about 0.4% by weight of feed. When incorporatedinto other organic matter (e.g., animal bedding), a composition of theinvention is added in amounts ranging from about 0.0125% to about 99.9%.When incorporated into a liquid (e.g., water (e.g., for filtration)), acomposition of the invention is added in amounts ranging from about0.0125% to about 100%. In some embodiments, a composition of theinvention is added to feedstuffs in amounts from about 0.025% to about0.2% by weight of feedstuff. Alternatively, compositions of theinvention are directly fed to animals as a supplement (e.g., in anamount ranging from about 2.5 to about 20 grams per animal per day). Oneof ordinary skill in the art immediately appreciates the amount to befed varies depending upon animal species, size, the type of feedstuff towhich a composition of the invention is added, bedding material, watersource, etc.

Compositions of the invention can be fed to any animal and humans. Whenadmixed with feedstuffs or used as a feed supplement, compositions ofthe invention decrease mycotoxin bioavailability, absorption or uptakeof mycotoxins by the animal, improve performance and/or health andreduce incidence of disease. In some embodiments, when, compositions ofthe invention are added to organic material that animals and humans comeinto contact with (e.g. bedding), compositions of the invention decreasemycotoxin bioavailability (e.g., decrease absorption and/or uptake ofmycotoxins by the animal) thereby improving performance and health andreducing incidence of disease. In some embodiments, compositions of theinvention are added to water that is intended for use by animals orhumans (e.g., for consumption or other purpose), thereby decreasingmycotoxin bioavailability (e.g., decrease absorption and/or uptake ofmycotoxins by an animal or human subject) and improving performance andhealth and reducing incidence of disease (e.g., compositions of theinvention decrease bioavailability, absorption or uptake of mycotoxins).In some embodiments, a composition of the invention is added to waterused for human consumption (e.g., water used for manufacture of juice,wine, water bottles, coffee, tea, milk or other type of consumedliquid). In some embodiments, a composition of the invention is added toenvironmental water (e.g., ponds, lakes, reservoirs, rivers, streams,irrigation channels, tanks used to house fish or other type of aquaticspecies, etc.). Thus, in some embodiments, a composition of theinvention (e.g., yeast cell wall extract comprising clay or claycomponent integrated into the cell wall) is utilized in the filtrationof liquids (e.g., consumable liquids (e.g., water used in beverageproduction, beverages)). For example, in some embodiments, a compositionof the invention is utilized as or in a filter, wherein a liquid (e.g.,consumable liquid (e.g., orange juice, apple juice, prune juice,grapefruit juice, cranberry juice, or other type of juice, beer, wine,distilled liquid, etc.)) is processed through a filter comprising acomposition of the invention, wherein the composition removes one ormore types of mycotoxins from the liquid.

As described in Examples 1-4, cultivation of yeast in the presence ofclay provides a dramatic increase in the yeast cell wall adsorption ofmycotoxins (e.g., from 6.917% when the yeast is not cultivated withclay, and reaching 73.553% and 79.337% when 1.0 and 2.0% of clay arerespectively included to the medium without the specific extraction ofthe glucan of the inner yeast cell wall layer (See, e.g., Example 2)).Moreover, the ratio of glucan:mannan increases from 1.066 to 1.366 withthe addition of clay. Despite a decrease of mannan, the concentration ofthe proteins of the cell wall increased. Also, the remnant fraction(e.g., representing losses of glucans, mannan, proteins, clay,N-acetylglucosamine and/or chitin present in the yeast cell wall duringthe extraction process) increased in the presence and surface area ofclay. Although a mechanism is not necessary to practice the inventionand the invention is not limited to any particular mechanism of action,in some embodiments, the increase is due to the enhancement of chitinfraction involved in compensatory mechanisms of the yeast due to changesof the environment and conditions of growth. Moreover, compositions ofthe present invention (comprising yeast cell wall extract from alteredyeast cells (e.g., yeast cells comprising clay and/or clay componentinterlaced into the yeast cell walls and/or cell walls comprisingaltered glucan and/or mannan structure)) provided a significant andunexpected ability to adsorb and/or sequester mycotoxins (e.g.,zearalenone (e.g., displaying a 79.33% efficacy compared to only a 44.7%efficacy for a conventional composition comprising a combination ofyeast cell wall extract to which a clay is later added on a dry blendbasis, See Examples 1-4)).

The use of an alternative method to extract clay interlaced yeast cellwall of clay interlaced yeast cells using a protease cut wasinvestigated (See Example 3). The specific extraction of the inner layer(glucan) of clay interlaced yeast cell wall generated an increase of thesequestering and adsorption properties of the clay interlaced yeast cellwall for mycotoxins (e.g., zearalenone). Moreover, cultivating yeastcells in a cell culture medium comprising clay at 1.0% and 2.0% enhancedsignificantly the sequestering and adsorption activity of clayinterlaced yeast cell wall with mycotoxins, (e.g. zearalenone). Forexample, a conventional composition comprising a combination of yeastcell wall extract to which a clay is later added on a dry blend basisaccounted for a 44.7% efficacy rate for sequestering mycotoxins,compared to a 85.89% efficacy rate for sequestering mycotoxins obtainedwith a composition of the present invention and an increase of aflatoxinB1 adsorption from 2.65 up to 53.70% (See, e.g., Example 3).

In some embodiments, the present invention provides methods forproducing yeast cells comprising a clay-interlaced yeast cell wall. Insome embodiments, yeast cells comprising a clay-interlaced yeast cellwall are produced on a variety of scales (e.g. test scale, batch-scale,pilot-scale, pre-production-scale, production-scale, commercial-scale,industrial scale). In some embodiments, yeast are grown in a fermenter.A fermenter may be of any suitable size (e.g. 5 liter . . . 10 liter . .. 25 liter . . . 50 liter . . . 100 . . . 500 liter . . . 1K liter . . .5K liter . . . 10K liter . . . 50K liter . . . 100K liter . . . 500Kliter . . . 1 million liter, etc.) to produce the desired scale of yeastfor use with the present invention (e.g. test-scale, pilot scale,industrial-scale, etc.). In some embodiments, media for growing yeastcan be of any suitable composition for growing yeast in accordance withthe present invention. Suitable nutrients are sources of carbon,nitrogen, phosphorus, magnesium, sulphur, potassium and trace elements.In some embodiments, nutrients are added to the culture inconcentrations (% w/w of the source compound) within the ranges(percentages by weight): Carbon source 0.01-20% (e.g. 0.05-10%),Nitrogen source 0.001-10% (e.g. 0.001-3%), Phosphorus source 0.001-5%(e.g. 0.01-0.5%), Magnesium source 0.001-0.2% (e.g. 0.001-0.2%), Sulphursource 0.01-0.25% (e.g. 0.01-0.25%), Potassium source 0.001-05% (e.g.0.01-0.25%), Organic nitrogen source 0.001-5% (e.g. 0.01-5%), and traceelements are added in excess. In some embodiments, yeast culture mediacomprises water, carbon source (e.g. sugar, glucose, dextrose, sugarcane, molasses, etc.), suitable nitrogen source (e.g. ammonia, urea,etc.), amino acid source (e.g. peptone, etc.), salts (e.g. sodiumchloride, calcium hipochloride, magnesium chloride, magnesium sulphate,zinc sulphate, etc.), and source of clay or clay component (e.g.zeolite, bentonite, aluminosilicate, montmorillonite, smectite,kaolinite, organoclay, mixtures thereof, etc.). In some embodiments,yeast culture media components may be present in any suitable amountsfor yeast cell growth (See e.g. Example 5). In some embodiments, thepresence of clay in yeast culture media presents unanticipatedcomplications to standard yeast growing protocols. In some embodiments,the presence of clay in culture media results in unusually large amountsof foaming in the fermentor. In some embodiments, the present inventionprovides antifoaming agents in the cell culture medium (e.g. nonsiliconemolecular defoamers, oil based defoamers (e.g. mineral oil, vegetableoil, white oil, etc.), powder defoamers (e.g. silica), water baseddefoamers, silicone based defoamers, polyethylene glycol polypropyleneglycol copolymers, alkyl polyacrylates, etc.). In some embodiments,antifoaming agents are required for increasing the scale of the presentinvention. In some embodiments, use of an antifoaming agent isassociated with an enhanced ability to scale up production of acomposition of the invention

EXPERIMENTAL

The following examples are provided in order to demonstrate and furtherillustrate certain preferred embodiments and aspects of the presentinvention and are not to be construed as limiting the scope thereof.

Example 1 Materials and Methods

Yeast Culture.

The following protocol was used for each Bioflow fermenter (BioFlow III,New Brunswick Scientific Co., Inc., Edison, N.J., U.S.A.) to grow theyeast Sacchromyces cerevisiae (active dry yeast (ADY) from Fermin,Alltech Inc., Batch #689, Yeast count: 2.38×10¹⁰ cells/gram, Viability:92.6%). The yeast inoculum was prepared by transferring 28 g of freshADY Fermin to a pre-warmed bottle of 250 mL sterile deionized water.Then, the solution was incubated at 30° C. (in water bath) for 20 minand swirled several times. The BioFlow media was composed of 66 g ofyeast extract, 10 g of peptone, 4 g of dextrose, 4 g of yeast nitrogenbase and 1750 mL of deionized water. A control batch was produced bygrowing yeast alone, which required an additional 250 mL of deionizedwater to the reactor volume. Three batches containing yeast andbentonite K10 (Fluka) were produced by adding 8, 16, and 32 g to thereactor. The Bioflow reactor media was warmed up at 30° C. and air wasinjected at 1 L/min flow rate during 10 min prior inoculation. Agitationwas set at 300 rpm and the media monitored and maintained at a minimumof pH 5.0 during the entire growth. An anti-foaming agent was added(Antifoam AES, 1:10, as needed). Ammonium phosphate dibasic (DAP) wasthen injected aseptically (4 g in 10 mL at pH 4.0). The previouslyre-suspended yeast was added to the fermentor. The glucose level wastested during growth with diabetic stripes (OneTouch, UltraMini,LifeScan, Inc., Milpitas, Calif., U.S.A.) and supplemental glucose wasadded when glucose level fell below 0.8 mg/mL. The agitation wasprogressively increased to 500 rpm over 2 h of incubation as well as theair flow (up to 4 L/min over 3 h). When half of the supplemental glucosesubstrate was consumed, additional bentonite was added (8, 16, 32 g in250 mL deionized water) to the reactor for a final concentration of0.5%; 1.0%; and 2.0%, respectively, of clay in the final media.

Yeast cultures were harvested when all sugar had been utilized. Thecontent of the BioFlow was collected into sterile bottles andcentrifuged at 4000 g for 20 min. The supernatant was removed and thepellet was washed with 0.125% NaCl in H2O. The pellet was separated into2 fractions by the distinct formation of 2 layers after centrifugation:(i) a clay containing layer and (ii) a yeast and clay containing layer.Yeast were then washed three times with 0.125% NaCl solution.

Clay Interlaced Yeast Cell Wall Extraction Method.

Two separate methods were used for the isolation of yeast cell wallfractions from yeast produced as described above.

In a first method, a ‘micro-method’ was used employing glass beads and aminibead beater (Bead-Beater, Model #1107900, Biospec Products, Inc.,Hamilton Beach/Proctor-Silex, Inc., Southern Pines, N.C., U.S.A.). Thepellet was resuspended with two volume of 10 mM Tris-Cl, pH 7.4 withphenylmethylsulfonofluoride (PMSF) and beat with glass beads (50:50,yeast slurry:beads) in a total volume of 5 mL for 30 sec with 1 mininterval rest, all the while on ice. The beating was repeated 10 timesor until 95% of the cells were disrupted. The beads were re-collectedand washed. The fractions were pooled and centrifuged at 4000 g for 20min. The pellets were then collected, freeze-dried and ground.

In a second method, the yeast pellet was resuspended with steriledeionized water to a concentration of 13 to 15% of dry matter. The yeastslurry was stirred at 60° C. The pH was adjusted using 10% NaOH to 8.0before adding enzyme at 0.3 mL/L. The temperature and stirringconditions were maintained over 8 h. The pH was monitored and adjustedevery 15 min (using the 10% NaOH) for the first two hours, and then thepH was monitored and adjusted every hour for the next six hours. Theslurry was transferred to sterile centrifuge bottles and centrifuged at4000 g for 20 min. The supernatant was discarded and the pellet washedwith three volume of cold sterile water, and then centrifuged again at4000 g for 20 min. The washing step was repeated two times before thepellet was frozen, freeze dried and ground.

Example 2 Characterization of Yeast Cell Wall Extracts IsolatedUtilizing Glass Beads and a Minibead Beater from Yeast Cells Cultivatedin the Absence and Presence of Clay

Yeast cells were disrupted after re-suspension of the cells in Tris-HClbuffer, pH 7.4 with PMSF using a micro-method using a bead-beater andglass beads as described (See Example 1). Yeast cell wall lysates werethen analyzed in order to characterize the yeast cell walls and theirability to adsorb mycotoxins (expressed as a percent of efficacycompared to total mycotoxins present) under physiological pH conditionsfor each individual mycotoxin considered. The overall adsorbing/bindingactivity was evaluated kinetically. Test samples comprised a minimum of5 levels up to 10 levels of mycotoxin concentrations tested with thedifferent yeast cell wall preparations used at a concentration between0.25 and 4 g/L dispersed in an aqueous medium with a fixed value of pH 4representative of digestive conditions of pH in the animal tract.Adsorption evaluation was calculated using a High Performance LiquidChromatography (abbrev. HPLC) coupled to fluorometric and diode-arraydetectors (e.g., to detect amounts of mycotoxin and mycotoxinadsorbed/sequestered).

Data is shown in FIG. 3. Yeast cell wall extracts obtained from yeastcells cultured in the presence of clay (clay interlaced yeast cells)display a significant, unexpected, ability to sequester and to adsorbzearalenone (e.g., displaying a 79.33% efficacy for yeast cell wallsextracted from yeast cells cultivated in the presence of 2% claycompared to only 6.91% efficacy of yeast cell walls extracted from yeastcells cultivated in the absence of clay. The 79.33 efficacy rate foryeast cell wall compositions extracted from yeast cells cultivated inthe presence of 2% clay was also significantly higher than previouslydocumented efficacy rates of only 44.7% for a conventional compositioncomprising a combination of yeast cell wall extract to which a clay islater added on a dry blend basis. The level of inclusion of thesequestrants product for AFB1 and ZEA were respectively of 0.1 and 0.4%in the reaction medium that was maintained at a constant pH of 4.0. Theassay was performed under orbital agitation during 90 min at 37° C. andthe amount of bound toxin evaluated using HPLC equipped with afluorescent detector.

Additionally, yeast grown/cultivated in the presence of clay displayedsignificant alteration in cell wall component/structure. For example, asthe amount of clay was increased, the ratio of mannan:glucan increases(e.g., as clay increases from none, 0.5%, 1.0% to 2.0%, themannan:glucan ratio increases from 1.01 to 1.2, 1.35 and 1.45,respectively. The total amount of protein also increased with increasingamounts of clay added to the cell culture medium.

Example 3 Characterization of Yeast Cell Wall Extracts IsolatedUtilizing Protease Cutting from Yeast Cells Grown/Cultivated in theAbsence and Presence of Clay

Yeast cells were treated with a protease as described in Example 1.Yeast cell wall lysates were then analyzed in order to characterize theyeast cell walls and their ability to adsorb mycotoxins (expressed as apercent of efficacy compared to total mycotoxins present) underphysiological pH conditions for each individual mycotoxin considered.The overall adsorbing activity was evaluated kinetically. Tests samplescomprised a minimum of 5 levels up to 10 levels of mycotoxinconcentrations tested with the different yeast cell wall preparationsused at a concentration between 0.25 and 4 g/L dispersed in an aqueousmedium with a fixed value of pH 4) representative of digestiveconditions of pH in the animal tract. Adsorption evaluation wascalculated using a HPLC coupled to fluorometric and diode-arraydetectors (e.g., to detect amounts of mycotoxin and mycotoxinadsorbed/sequestered).

Data is shown in FIG. 4. Clay interlaced yeast cell wall extractsobtained from yeast cells cultured in the presence of clay displayed asignificant, unexpected, ability to sequester and/or adsorb zearalenoneand aflotoxin B1. For example, yeast cell wall extracts obtained fromyeast grown in the presence of 2.0% clay displayed an 85.89% efficacyfor zearalenone whereas yeast cell wall extracts from yeast cultivatedin the absence of clay display only a 69% adsorption efficacy rate. Clayinterlaced yeast cell wall extracts obtained from yeast grown in thepresence of 2.0% clay displayed a 53.7% efficacy for aflatoxin B1whereas yeast cell wall extracts from yeast cultivated in the absence ofclay display only a 2.65% adsorption efficacy rate. Additionally, clayinterlaced yeast grown/cultivated in the presence of clay displayedsignificant alteration in cell wall component/structure. The level ofinclusion of the sequestrants product for AFB1 and ZEA were respectivelyof 0.1 and 0.4% in the reaction medium that was maintained at a constantpH of 4.0. The assay was performed under orbital agitation during 90 minat 37° C. and the amount of bound toxin evaluated using HPLC equippedwith a fluorescent detector.

The method of Example 1 was used with alternate sources of yeast toevaluate the influence of a smectite clay (American Colloid Company,Arlighton Height, Ill., USA) added at 1.0% in the growing media on thecomposition of the clay interlaced yeast cell wall material. Three yeasttypes were investigated belonging to Saccharomyces cerevisiae, ADYFermin (08-032/460-89), a baker's yeast from Levapan (Batch #7169281,Levapan S.A., Bogota, Columbia) and an active dry yeast from DCL (lot#1390, DCL Yeast Ltd., Alloa, Great Britain).

Variation between the clay interlaced yeast cell wall were observed withlevels of 19.9, 17.0, and 10.3% of glucan; 10.6, 10.4, and 8.4% ofmannan; and 1.5, 1.4, 0.9% of chitin (N-acetyl-glucosamine) present inthe yeast cell wall (and expressed by reference to the total cell) forADY Fermin, Levapan, DCL clay interlaced yeast cell walls priorhydrolysis.

The sequestration efficacy of the produced material exhibited alsodifferences according to the yeast cell type selected (See, e.g. FIG.9). The variations observed in terms of efficacy were also related tothe type of mycotoxin considered.

Example 4 Electron Microscopy Imaging of Yeast Cell Wall Extracts fromYeast Cells Grown/Cultivated in the Absence and Presence of Clay

Experiments were conducted during development of embodiments of theinvention in order to characterize and observe several yeast samples(See, e.g., FIG. 2). The samples were prepared by the filtration of arehydrated solution of yeast in 2.5% glutaraldehyde (GTA) in 0.85% NaClsolution. The solution was then filtered through a nylon nucleopore 13mm diam., 0.1 μm pore size pre-wetted with 0.85% NaCl. The filter wasthen transferred to a Petri dish and covered with drops ofGTA/cacodylate (Cac) fixative at room temperature during 90 min. Thefilters were then rinsed with 0.1 M Na Cac pH 7.2. The secondaryfixation was achieved by placing the filters in a tube during 60 minwith 100 μL of 2% osmium tetroxide in 0.1 M Na Cac pH 7.2. The sampleswere then rinsed with 0.1 M Na Cac pH 7.2 and 3 times with deionizedwater. The dehydration of the sample was achieved by ethanol series (25%to 100%). Then, the samples were freeze-dried, mounted on a stubprepared with a carbon tape for conductivity purpose, and coated withAu/P alloy. The observations were made at 3.0 keV on an S-4300 FESEM(Hitachi, Japan). To remove any unspecific interaction between the yeastand clay, a nitrogen high pressurized gas stream was applied on eachmounted sample before coating with Au/P.

Example 5 Semi-Industrial Scaling-Up of the Production of Yeast CellWall Cultivated with Clay

Scaled-Up Yeast Culture.

A 150 L fermenter (ML-4100, New Brunswick Scientific Co., Inc., Edison,N.J., U.S.A.) was used to grow the yeast Sacchromyces cerevisiae (activedry yeast (ADY) from Fermin, Alltech Inc., Batch #609, Yeast count:2.38×10¹⁰ cells/g, Viability: 92.6%). The yeast inoculum was prepared bytransferring 0.84 kg of fresh ADY Fermin to a pre-autoclaved (121° C.during 40 min) 19 L carboy with tubing, covered with a BioShieldcontaining 7.5 L of water and that has been maintained after autoclavingat 30° C. in an incubator overnight. Two 19 L Food carboy, covered witha BioShield were prepared by adding 9 L of water, 6 kg of dextrose and astir bar. After mixing and dissolution of the carbon source, the foodmedia was autoclaved (121° C. during 40 min). A Nitrogen solution wasprepared using 1 L sterile capped bottle containing 250 mL of deionizedwater, 120 g of diammonium phosphate adjusted to pH 4.0-4.1 withconcentrated HCl. Two 1 L sterile capped bottle of Food Nitrogen wereprepared by adding 700 mL of deionized water, 192 g of diammoniumphosphate adjusted to pH 4.0-4.1 with concentrated HCl. A Base solutionwas prepared in a 19 L carboy with tubing, covered with a BioShield andcontaining 13.5 L of water, 1.5 L KOH. The tubing was then connected toa peristaltic pump. An anti foaming agent (Antifoam AES, 1:10) solutionwas prepared in a 19 L carboy with tubing, covered with a BioShield andcontaining 12 L of water, 3 L of antifoaming agent (Antifoam AES, 3 kg)and mixed. The tubing was then connected to a peristaltic pump. The 150L fermentor media was composed of 1.98 kg amber, 0.3 kg of peptone, 0.12kg of dextrose, 0.12 kg of yeast nitrogen base, 0.516 g of smectite clay(American Colloid Company, Arlighton Height, Ill., USA) and 60 L ofwater that was brought to 121° C., 15 psi for 1 h with agitation. Themedium was cooled down to 30° C. and this temperature was maintainedthroughout the propagation.

The propagation was performed on the 150 L fermenter maintained at 30°C. with mild agitation (70% of power) and air injection (at 5 psi) priorinoculation and during entire fermentation. The inoculum containing 0.84kg of ADY in 7.5 L of water was stirred for 20-30 min prior toinoculation in the 150 L Fermentor. One bottle of Food Nitrogen wasadded to each Food carboy under mixing. The Nitrogen solution was pumpedinto the 150 L fermentor and allowed to mix for a minimum of 10 minprior to inoculation. The antifoam Carboy was attached and theanti-foaming agent pumped through the tubing into the 150 L fermentor asneeded. A foam probe was set inside the fermentor to monitor the foamingand to allow supplementing correctly with the anti-foaming agent. TheBase solution was attached and pumped through the tubing into the 150 Lfermentor as needed. The evolution of the pH of the 150 L fermentormedia was monitored and maintained at a minimum of pH 5.0 during theentire growth. The inoculation was performed by attaching the inoculumCarboy to the port and by pumping the content into the 150 L fermentor.Mixing of the inoculum in the fermentor was done for 20-30 min prior tofirst sampling. The foam was monitored throughout the propagation,adjusting air and agitation up hourly. The pH was monitored internallyand externally and adjusted as necessary to maintain a pH of 5.0 orhigher. The glucose level was tested during growth with diabetic strips(OneTouch, UltraMini, LifeScan, Inc., Milpitas, Calif., U.S.A.) andsupplemental glucose was added when glucose level fell below 0.8 mg/mLby slowly pumping in the Food solution or speeding up graduallyovertime. If the sugar level rose above 0.8 mg/mL, the feed rate wasslowed down or shut off if necessary.

Yeast cultures were harvested when all sugar had been utilized. Thecontent of the 150 L fermenter was collected into sterile bottles andcentrifuged at 4000 g for 20 min. The supernatant was removed and thepercentage of dry matter of the washed yeast measured. The material wasthen transferred back to the 150 L fermenter and water was added tobring the slurry from 9-11% to a concentration 13-15% of dry matter.Agitation was maintained at all times.

Clay Interlaced Yeast Cell Wall Extraction Through Enzyme Hydrolysis.

The 13-15% of dry matter yeast slurry was stirred at 60° C. The pH wasadjusted using 10% NaOH to 8.0 before adding enzyme at 0.3 mL/L. Thetemperature and stirring conditions were maintained over 8 h. The pH wasmonitored and adjusted every 15 min (using the 10% NaOH) for the firsttwo hours, and then the pH was monitored and adjusted every hour for thenext six hours. The slurry was transferred to sterile centrifuge bottlesand centrifuged at 4000 g for 20 min. The supernatant was discarded andthe pellet washed with three volume of cold sterile water, and thencentrifuged again at 4000 g for 20 min. The washing step was repeatedtwo times before the pellet was frozen, freeze dried and ground. Theincrease of the temperature during the spray drying phase resulted in aslightly higher yield and less accumulation of product in the spraydrier.

The inclusion of the clay material can be followed by the change in theash concentration of the sample reaching values around 20% for the clayinterlaced yeast cell wall compared to a 5% concentration in a yeastcell wall extract that is not containing any clay material (See, e.g.FIG. 6). A significant difference in terms of composition between theADY Fermin yeast cell line produced previously in the Bioflow fermenterscompared to the 150 L fermenter was also found with a decrease of theglucan and mannan composition in the large scale production but also anincrease of the chitin content of the yeast cell wall (1.5% to 3%)accounting for the responses by the yeast cell wall to perturbing agentand implicating the cell wall signaling pathway.

Semi-industrial scale clay interlaced yeast cell wall extract productswere evaluated for sequestration efficacy of mycotoxins (See, e.g. FIG.7), and the results confirm increase of mycotoxin adsorptioncapabilities of clay interlaced yeast cell wall extracts.

Example 6 Production of Clay Interlaced Yeast Cell Wall Utilizing anIndustrial Source of Sugar

Yeast Culture.

Sacchromyces cerevisiae (active dry yeast (ADY) from Fermin, AlltechInc., Yeast count: 2.38×10¹⁰ cells/g, Viability: 92.6%) were grown in aBioflow fermenter (BioFlow III, New Brunswick Scientific Co., Inc.,Edison, N.J., U.S.A.). The yeast inoculum was prepared by transferring29 g of fresh ADY Fermin to a pre-warmed bottle of 87 ml steriledeionized water. Then, the solution was incubated at 30° C. (in waterbath) for 20 min and swirled several times. The BioFlow media wascomposed of 0.048 g calcium hipochloride, 0.24 g magnesium sulphate,0.168 g zinc sulphate, 0.24 g magnesium chloride, 2.4 g (2.5 mL ofprepared food) sugar cane must, 7.5 g smectite clay (0.5% in the finalmedia, (American Colloid Company, Arlighton Height, Ill., USA)) and 1440mL of deionized water. The sugar cane must is a 30% of total reducingsugars (TRS) solution of molasses diluted with water. Preparation of themust was made with 669 g of molasses (62.8% TRS) and 731 mL of deionizedwater. A nitrogen source was prepared with 54.5 g of urea in 163.5 mL ofdeionized water.

The Bioflow reactor media was warmed up at 30° C. and air was injectedat 1 L/min flow rate during 10 min prior inoculation. Agitation was setat 300 rpm and the media monitored and maintained at a minimum of pH 5.0during the entire growth using phosphoric acid, 85%. An anti-foamingagent was added (Antifoam AES, 1:10, as needed). The previouslyre-suspended yeast was added to the fermentor. The glucose level wastested during growth with diabetic stripes (OneTouch, UltraMini,LifeScan, Inc., Milpitas, Calif., U.S.A.) and supplemental food (fromthe sugar cane must) was added when glucose level fell below 0.8 mg/mL.The agitation was progressively increased to 500 rpm over 2 h ofincubation as well as the air flow (up to 4 L/min over 3 h). The finalconcentration of clay to the reactor was 0.5% in the final media.

The amount of molasses to be added to the fermenter depended on theefficiency of the yeast to utilize the sugar and was comprised between400 and 600 g. Overfeeding of molasses encountered production issuesresulting in the incapacity to generate any yeast biomass throughfermentation. Yeast cultures were harvested when no further growth wasobserved. The content of the BioFlow was collected into sterile bottlesand centrifuged at 4000 g for 20 min. The supernatant was removed andthe pellet was washed with 0.125% NaCl in H₂O. No separate fraction wasfound when molasses were used to perform the propagation of the yeast.Yeasts were then washed three times with 0.125% NaCl solution.

Clay Interlaced Yeast Cell Wall Extraction Method.

The yeast pellet was resuspended with sterile deionized water to aconcentration of 13 to 15% of dry matter. The yeast slurry was stirredat 60° C. The pH was adjusted using 10% NaOH to 8.0 before adding enzymeat 0.3 mL/L. The temperature and stirring conditions were maintainedover 8 h. The pH was monitored and adjusted every 15 min (using the 10%NaOH) for the first two hours, and then the pH was monitored andadjusted every hour for the next six hours. The slurry was transferredto sterile centrifuge bottles and centrifuged at 4000 g for 20 min. Thesupernatant was discarded and the pellet washed with three volume ofcold sterile water, and then centrifuged again at 4000 g for 20 min. Thewashing step was repeated two times before the pellet was frozen, freezedried and ground.

The sequestration efficacy of the produced material exhibited alsodifferences according to the carbon source used to propagate the yeast(See, e.g. FIG. 8). The variations observed in terms of efficacy werealso related to the type of mycotoxin considered. The composition of thematerial was also different from the composition of the materialpreviously produced with dextrose as sole source of carbon. Levels of13.4% of glucan; 17.8% of mannan; and 2.7% of chitin(N-acetyl-glucosamine) present in the yeast cell wall (and expressed byreference to the total cell) were found.

Example 7 In Vivo Efficacy Against Fusarium Mycotoxicoses

One-day-old Hybrid turkey poults (Hybrid Turkeys, Kitchener, ON, Canada)were individually weighed, wing-banded and distributed randomly intogroups at the Arkell Poultry Research Station of the University ofGuelph. Poults were randomly assigned to each of 5 diets. Poults wereinitially maintained at 32° C., and the temperature was graduallyreduced by 3° C. per week to reach a temperature of 21° C. by the end ofweek 4. This temperature was maintained for the duration of theexperiment. Turkey poults were fed corn, wheat and soybean meal-basedstarter (0-3 week), and grower (4-6 week) diets formulated with controlgrains, control+0.2% clay interlaced yeast cell wall, contaminatedgrains, and contaminated grains+0.2% clay interlaced yeast cell wall.The control diet was formulated to meet or exceed the minimum nutrientrequirements of turkeys according to the NRC (1994).Mycotoxin-contaminated diets were prepared by replacing 25 and 10% and26 and 5% of the control corn and wheat with contaminated corn and wheatnaturally contaminated with Fusarium mycotoxins during starter andgrower phases, respectively. The levels of replacement of control grainswith the contaminated grains were calculated in order to achieve amycotoxin challenge of about 4 mg DON/kg of diet during starter andgrower phases. Clay interlaced yeast cell wall extract (abbrev. CIYCW intables) supplemented diets were prepared by substituting control corn inthe diets with 0.2% of clay interlaced yeast cell wall extract. Feed andwater were provided ad libitum. Representative feed samples were takenat the beginning of each phase for proximate and mycotoxin analyses.Dietary contents of protein, dry matter and ash were determinedaccording to the Association of Official Analytical Chemists (1980). Thediet formulations and nutrient contents are presented in Table 1. Theexperimental procedures were approved by the University of Guelph AnimalCare Committee following the guidelines of the Canadian Council onAnimal Care.

TABLE 1 Composition of experimental diets (%). Control + Contaminated +Ingredients Control CIYCW Contaminated CIYCW Starter diet (0-3 wk) Corn36.00 35.80 11.02 10.82 Contaminated corn 24.98 24.98 Wheat 10.00 10.00Contaminated wheat 0.00 0.00 10.00 10.00 Soybean meal 45.00 45.00 45.0045.00 Monocalcium phosphate 2.30 2.30 2.30 2.30 Calcium carbonate 1.841.84 1.84 1.84 Fat/Tallow 3.00 3.00 3.00 3.00 Salt 0.40 0.40 0.40 0.40DL-Methionine 0.22 0.22 0.22 0.22 HCl-Lysine 0.15 0.15 0.15 0.15 Vitaminand mineral premix¹ 1.00 1.00 1.00 1.00 Anticoccidial² 0.10 0.10 0.100.10 CIYCW 0.20 0.20 Calculated values ME, kcal/kg 2800 Crude Protein26.50 Lysine 1.60 Methionine 0.62 Calcium 1.20 Available phosphorus 0.60Analyzed values Crude protein 26.41 24.97 27.75 26.70 DM 88.70 89.0388.99 89.14 Ash 8.10 6.97 7.12 7.00 Grower diet (4-6 wk) Corn 42.6842.48 16.86 16.66 Contaminated corn 25.82 25.82 Wheat 5.00 5.00Contaminated wheat 5.00 5.00 Soybean meal 42.00 42.00 42.00 42.00Monocalcium phosphate 2.20 2.20 2.20 2.20 Calcium carbonate 1.40 1.401.40 1.40 Fat/Tallow 5.00 5.00 5.00 5.00 Salt 0.40 0.40 0.40 0.40DL-Methionine 0.16 0.16 0.16 0.16 HCl-Lysine 0.06 0.06 0.06 0.06 Vitaminand mineral premix¹ 1.00 1.00 1.00 1.00 Anticoccidial² 0.10 0.10 0.100.10 CIYCW 0.20 0.20 Calculated values ME, kcal/kg 3050 Crude Protein 23Lysine 1.36 Methionine 0.5 Calcium 1.1 Available phosphorus 0.52Analyzed values Crude protein 23.31 24.29 24.27 27.70 DM 89.30 88.9988.54 88.38 Ash 6.33 6.39 6.73 6.75 ¹Vitamin-mineral mixture providedper kilogram of diet: vitamin A (all-trans-retinyl palmitate), 8,800 IU;cholecalciferol, 3,300 IU; vitamin E (all-rac-α-tocopheryl acetate), 40IU; menadione, 3.3 mg; thiamin, 4.0 mg; riboflavin, 8.0 mg; pantothenicacid, 15.0 mg; niacin, 50 mg; pyridoxine, 3.3 mg; choline, 600 mg; folicacid, 1.0 mg; biotin, 220 μg; vitamin B₁₂, 12 μg; ethoxyquin, 120 mg;manganese, 70 mg; zinc, 70 mg; iron, 60 mg; copper, 10 mg; iodine, 1.0mg; selenium, 0.3 mg. ²Monensin sodium, 10%.

Dietary concentrations of deoxynivalenol, 15-acetyl-deoxynivalenol,zearalenone, fumonisin and ochratoxin A are given in Table 2. Othermycotoxins were below the method detection limits which were 0.12 mg/kgfor nivalenol, 0.05 mg/kg for 3-acetyl-deoxynivalenol, 0.07 mg/kg forneosolaniol, 0.06 mg/kg for diacetoxyscirpenol and T-2 toxin and 0.04mg/kg for HT-2 toxin, and 0.001 mg/kg for aflatoxins. The detectionlimits for deoxynivalenol, 15-acetyl-deoxynivalenol, zearalenone,fumonisin and ochratoxin A were 0.06, 0.05, 0.025, 0.05 and 0.0003mg/kg, respectively.

TABLE 2 Mycotoxin concentrations (μg/g) in experimental diets.Mycotoxin¹ 15-acetyl- Diet Deoxynivalenol deoxynivalenol ZearalenoneFumonisin Ochratoxin A Starter (0-3 wk) Control 0.44 0.055 <0.025  BDL²0.46 Control + CIYCW 0.53 0.087 <0.025 BDL 0.79 Contaminated 3.3 0.170.35 56 BDL Contaminated + CIYCW 4.1 0.17 0.47 BDL BDL Grower (4-6 wk)Control 0.44 0.12 BDL BDL 0.62 Control + CIYCW 0.37 0.12 BDL BDL 0.71Contaminated 3.7 0.29 0.34 61 1.0 Contaminated + CIYCW 3.2 0.28 0.27 630.35 ¹Other mycotoxins, including diacetoxyscirpenol, T-2 toxin,nivalenol, 3-acetyl-DON, neosolaniol, HT-2 toxin, and aflatoxins werealso measured in the experimental diets, but were not detected. ²Belowdetection limit.

The feeding of contaminated grains did not significantly affect the bodyweight gain, feed consumption and efficiency of feed utilization at theend of starter phase (Table 3). Feeding contaminated diet significantlyincreased the body weight gain and improved the feed efficiency comparedto control at the end of grower phase. There was no effect of the dieton the feed intake during grower phase (Table 3). At the end of growerphase, supplementation of clay interlaced yeast cell wall extract to thecontaminated diets increased the body weight gain, feed consumption andimproved the efficiency of feed utilization compared to control. Bodyweight gain and feed efficiency over 6 week experimental period weresignificantly higher in the birds fed contaminated diets andcontaminated diets supplemented with clay interlaced yeast cell wallextract.

TABLE 3 Effect of dietary Fusarium mycotoxins on turkey performance¹Diet 0-3 wk 4-6 wk 0-6 wk Body weight gain (g/bird) Control 474.501420.81 1895.32 Control + CIYCW 501.45 1461.74 1963.19 Contaminated511.93 1572.97 2084.90 Contaminated + CIYCW 502.00 1627.63 2129.64 SEM15.35 29.48 37.59 Control vs. Control + CIYCW  NS² NS NS Control vs.Contaminated NS 0.0023 0.002 Control vs. Contaminated + CIYCW NS 0.00020.0004 Contaminated vs. Contaminated + NS NS NS CIYCW Feed intake(g/bird/day) Control 32.44 117.85 75.14 Control + CIYCW 33.54 116.8775.20 Contaminated 33.75 119.86 76.81 Contaminated + CIYCW 33.87 124.4079.13 SEM 0.91 2.21 1.40 Control vs. Control + CIYCW NS NS NS Controlvs. Contaminated NS NS NS Control vs. Contaminated + CIYCW NS 0.05 NSContaminated vs. Contaminated + NS NS NS CIYCW Feed efficiency (bodyweight gain/feed intake) Control 0.69 0.57 0.60 Control + CIYCW 0.710.59 0.62 Contaminated 0.71 0.61 0.63 Contaminated + CIYCW 0.71 0.620.64 SEM 0.01 0.008 0.008 Control vs. Control + CIYCW NS NS NS Controlvs. Contaminated NS 0.0027 0.004 Control vs. Contaminated + CIYCW NS0.0007 0.001 Contaminated vs. Contaminated + NS NS NS CIYCW ¹Values areleast square means; n = 4 pens for body weight gain, feed intake andfeed efficiency (7-8 birds/pen/phase). ²P > 0.05

The feeding of contaminated grains increased (P<0.05) eosinophil countsat week 6 (Table 4). Supplementation of the contaminated diets with clayinterlaced yeast cell wall extract prevented this. Supplementation ofclay interlaced yeast cell wall extract to the control dietsignificantly increased the hematocrit compared to un-supplementedcontrol. There was a significant reduction in the concentration ofglucose and activities of γ-glutamyl transferase in the birds fedcontaminated diet at week 3 compared to control (Table 5).Supplementation of clay interlaced yeast cell wall extract preventedthis. Clay interlaced yeast cell wall extract supplementation to thecontaminated diets significantly increased the concentrations of uricacid compared to control at week 3 and 6. There was a significantdecrease in the activity of lactate dehydrogenase at week 3 in the birdsfed contaminated diet+clay interlaced yeast cell wall extract comparedto control.

TABLE 4 Effect of dietary Fusarium mycotoxins on hematology¹ Diet 3 wk 6wk Hemoglobin (g/L) Control 93.50 105.88 Control + CIYCW 98.12 107.88Contaminated 93.50 109.75 Contaminated + CIYCW 95.87 106.38 SEM 2.271.80 Control vs.. Control + CIYCW  NS² NS Control vs. Contaminated NS NSControl vs. Contaminated + CIYCW NS NS Hematocrit (L/L) Control 0.300.31 Control + CIYCW 0.32 0.31 Contaminated 0.30 0.32 Contaminated +CIYCW 0.30 0.32 SEM 0.005 0.007 Control vs. Control + CIYCW 0.05 NSControl vs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NSMCHC (g/L) Control 302.80 335.38 Control + CIYCW 300.88 345.25Contaminated 303.13 336.13 Contaminated + CIYCW 310.88 331.63 SEM 5.445.52 Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NSControl vs. Contaminated + CIYCW NS NS WBC (10⁹/L) Control 15.37 16.75Control + CIYCW 18.71 16.75 Contaminated 17.96 16.07 Contaminated +CIYCW 18.93 19.96 SEM 1.93 2.26 Control vs. Control + CIYCW NS NSControl vs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NSHeterophils (10⁹/L) Control 6.20 9.37 Control + CIYCW 8.36 9.19Contaminated 7.98 8.71 Contaminated + CIYCW 7.86 10.36 SEM 0.93 1.26Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NS Controlvs. Contaminated + CIYCW NS NS Lymphocytes (10⁹/L) Control 7.37 5.54Control + CIYCW 8.00 5.61 Contaminated 8.60 5.48 Contaminated + CIYCW8.92 8.54 SEM 1.22 1.29 Control vs. Control + CIYCW NS NS Control vs.Contaminated NS NS Control vs. Contaminated + CIYCW NS NS Monocytes(10⁹/L) Control 0.71 0.52 Control + CIYCW 1.30 0.65 Contaminated 0.560.75 Contaminated + CIYCW 0.93 0.25 SEM 0.29 0.22 Control vs. Control +CIYCW NS NS Control vs. Contaminated NS NS Control vs. Contaminated +CIYCW NS NS Eosinophils (10⁹/L) Control 0.27 0.15 Control + CIYCW 0.380.34 Contaminated 0.34 0.38 Contaminated + CIYCW 0.33 0.06 SEM 0.110.079 Control vs. Control + CIYCW NS NS Control vs. Contaminated NS 0.04Control vs. Contaminated + CIYCW NS NS Basophils (10⁹/L) Control 0.790.61 Control + CIYCW 0.65 0.89 Contaminated 0.47 0.74 Contaminated +CIYCW 0.87 0.71 SEM 0.19 0.18 Control vs. Control + CIYCW NS NS Controlvs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NS ¹Valuesare least square means; for each diet and phase n = 4 pens and 2 birdsper pen. ²P > 0.05

TABLE 5 Effect of dietary Fusarium mycotoxins on plasma chemistry¹ Diet3 wk 6 wk Calcium (mmol/L) Control 3.05 2.94 Control + CIYCW 3.15 2.97Contaminated 3.05 3.03 Contaminated + CIYCW 3.13 3.14 SEM 0.04 0.04Control vs. Control + CIYCW  NS² NS Control vs. Contaminated NS NSControl vs. Contaminated + CIYCW NS 0.002 Phosphorus (mmol/L) Control2.57 2.46 Control + CIYCW 2.59 2.44 Contaminated 2.67 2.47Contaminated + CIYCW 2.64 2.64 SEM 0.08 0.06 Control vs. Control + CIYCWNS NS Control vs. Contaminated NS NS Control vs. Contaminated + CIYCW NS0.05 Total Protein (g/L) Control 29.12 31.25 Control + CIYCW 30.12 31.12Contaminated 29.62 32.62 Contaminated + CIYCW 29.75 34.25 SEM 0.52 0.68Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NS Controlvs. Contaminated + CIYCW NS 0.003 Albumin (g/L) Control 8.37 8.37Control + CIYCW 8.12 8.62 Contaminated 8.25 8.50 Contaminated + CIYCW8.75 9.00 SEM 0.29 0.25 Control vs. Control + CIYCW NS NS Control vs.Contaminated NS NS Control vs. Contaminated + CIYCW NS NS Globulin (g/L)Control 20.75 22.87 Control + CIYCW 22.00 22.50 Contaminated 21.37 24.12Contaminated + CIYCW 21.00 25.25 SEM 0.55 0.57 Control vs. Control +CIYCW NS NS Control vs. Contaminated NS NS Control vs. Contaminated +CIYCW NS 0.006 Albumin:Globulin ratio Control 0.40 0.36 Control + CIYCW0.37 0.38 Contaminated 0.38 0.35 Contaminated + CIYCW 0.42 0.35 SEM 0.010.01 Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NSControl vs. Contaminated + CIYCW NS NS Glucose (mmol/L) Control 18.3517.82 Control + CIYCW 18.13 17.45 Contaminated 17.31 17.52Contaminated + CIYCW 17.63 17.23 SEM 0.37 0.34 Control vs. Control +CIYCW NS NS Control vs. Contaminated 0.05 NS Control vs. Contaminated +CIYCW NS NS Cholesterol (mmol/L) Control 4.12 4.17 Control + CIYCW 3.994.23 Contaminated 4.10 4.04 Contaminated + CIYCW 4.03 3.73 SEM 0.12 0.13Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NS Controlvs. Contaminated + CIYCW NS 0.02 Total Bilirubin (umol/L) Control 5.372.37 Control + CIYCW 5.87 2.37 Contaminated 4.87 2.12 Contaminated +CIYCW 5.12 2.62 SEM 0.70 0.38 Control vs. Control + CIYCW NS NS Controlvs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NSγ-glutamyl-transferase (U/L) Control 1.75 1.75 Control + CIYCW 2.00 1.50Contaminated 0.75 1.87 Contaminated + CIYCW 0.87 1.00 SEM 0.33 0.18Control vs. Control + CIYCW NS NS Control vs. Contaminated 0.04 NSControl vs. Contaminated + CIYCW NS 0.008 Aspartate aminotransferase(U/L) Control 211.38 212.63 Control + CIYCW 226.25 207.75 Contaminated226.75 211.63 Contaminated + CIYCW 205.00 203.75 SEM 8.15 6.42 Controlvs. Control + CIYCW NS NS Control vs. Contaminated NS NS Control vs.Contaminated + CIYCW NS NS Creatine Kinase (U/L) Control 1352.63 1047.13Control + CIYCW 1309.38 907.63 Contaminated 1649.25 953.38Contaminated + CIYCW 1147.00 1086.63 SEM 173.46 145.41 Control vs.Control + CIYCW NS NS Control vs. Contaminated NS NS Control vs.Contaminated + CIYCW NS NS Amylase (U/L) Control 809.63 877.38 Control +CIYCW 821.63 764.88 Contaminated 872.50 913.25 Contaminated + CIYCW891.38 902.88 SEM 57.27 54.54 Control vs. Control + CIYCW NS NS Controlvs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NS Lipase(U/L) Control 5.37 2.87 Control + CIYCW 4.37 4.50 Contaminated 4.75 3.62Contaminated + CIYCW 5.87 4.25 SEM 0.94 0.72 Control vs. Control + CIYCWNS NS Control vs. Contaminated NS NS Control vs. Contaminated + CIYCW NSNS Uric acid (U/L) Control 247.75 167.13 Control + CIYCW 221.50 144.38Contaminated 292.50 164.75 Contaminated + CIYCW 334.50 279.00 SEM 28.2324.77 Control vs. Control + CIYCW NS NS Control vs. Contaminated NS NSControl vs. Contaminated + CIYCW 0.03 0.003 Lactate dehydrogenase (U/L)Control 664.88 531.00 Control + CIYCW 661.75 542.13 Contaminated 646.63469.25 Contaminated + CIYCW 566.13 497.63 SEM 30.24 20.84 Control vs.Control + CIYCW NS NS Control vs. Contaminated NS 0.04 Control vs.Contaminated + CIYCW 0.02 NS Glutamate dehydrogenase (U/L) Control 4.622.87 Control + CIYCW 3.25 2.62 Contaminated 4.25 2.37 Contaminated +CIYCW 3.50 2.50 SEM 0.70 0.36 Control vs. Control + CIYCW NS NS Controlvs. Contaminated NS NS Control vs. Contaminated + CIYCW NS NS ¹Valuesare least square means; for each diet and phase n = 4 pens and 2 birdsper pen. ²P > 0.05

The feeding of contaminated grains significantly decreased theactivities of lactate dehydrogenase at week 6 compared to control (Table5). Supplementation of clay interlaced yeast cell wall extract preventedthis. There was a significant increase in the concentrations of calciumand phosphorus in the birds fed contaminated and clay interlaced yeastcell wall extract diet compared to control at week 6. The same diet atweek 6 also significantly decreased the activities of γ-glutamyltransferase compared to control. A significant increase in theconcentrations of total protein and globulin, and decrease incholesterol levels were observed in the birds fed contaminated diet whensupplemented with clay interlaced yeast cell wall extract.

The feeding of grains naturally contaminated with Fusarium mycotoxins toturkeys resulted in a hormetic response with respect to body weight gainand feed efficiency. Feed-borne Fusarium mycotoxins resulted in someeffects on blood parameters compared to controls including increasedeosinophil counts and decreased lactate dehydrogenase activities at week6 and decreased glucose concentrations and gamma-glutamyl transferaseactivity at week 3. The feeding of clay interlaced yeast cell wallextract prevented all of these effects. The feeding of clay interlacedyeast cell wall extract resulted in numerical increases (P>0.05) ingrowth compared to the feeding of unsupplemented contaminated grains.

All publications and patents mentioned in the above specification areherein incorporated by reference. Various modifications and variationsof the described compositions and methods of the invention will beapparent to those skilled in the art without departing from the scopeand spirit of the invention. Although the invention has been describedin connection with specific preferred embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. Indeed, various modifications of thedescribed modes for carrying out the invention that are obvious to thoseskilled in the relevant fields are intended to be within the scope ofthe present invention.

What is claimed is:
 1. A method of reducing bioavailability ofmycotoxins to an animal or human comprising: a) providing i.) acomposition comprising a clay or clay component interlaced yeast cellwall extract; and ii) a material consumed by animal or human; b)incorporating said clay or clay component interlaced yeast cell wallextract into said material to produce a clay or clay componentinterlaced yeast cell wall extract incorporated material; and c)allowing said animal or human to consume said clay or clay componentinterlaced yeast cell wall extract incorporated material.
 2. The methodof claim 1, wherein said material is a feedstuff.
 3. The method of claim2, wherein about 0.0125% to about 0.4% of said composition comprising aclay or clay component interlaced yeast cell wall extract is added byweight to said feedstuff.
 4. The method of claim 1, wherein saidmaterial is bedding.
 5. The method of claim 4, wherein about 0.0125% toabout 99.0% of said composition comprising a clay or clay componentinterlaced yeast cell wall extract is added by weight to said bedding.6. The method of claim 1, wherein said material is a liquid.
 7. Themethod of claim 6, wherein about 0.0125% to about 99.0% of saidcomposition comprising a clay or clay component interlaced yeast cellwall extract is added by weight to said liquid.
 8. The method of claim1, wherein said animal is selected from the group consisting of avian,bovine, porcine, equine, ovine, and caprine, piscines, shellfish,camelids, feline, canine, and rodent species.
 9. The method of claim 1,wherein said composition comprising a clay or clay component interlacedyeast cell wall extract sequesters one or more types of mycotoxins. 10.The method of claim 2, wherein said feedstuff is selected from the groupconsisting of a Total Mixed Ration (TMR), a forage, a pellet, aconcentrate, a premix, grain, distiller grain, molasses, fiber, fodder,grass, hay, kernel, leaves, meal, distiller solubles, and a feedsupplement.
 11. The method of claim 1, further comprising incorporatingan additional agent into said clay or clay component interlaced yeastcell wall extract incorporated material, wherein said agent is selectedfrom the group consisting of an esterase, epoxidase, yeast and bacterialstrain.
 12. A method of reducing bioavailability of mycotoxins within asubject comprising administering to said subject a clay or claycomponent interlaced yeast cell wall extract incorporated material underconditions such that the bioavailability of mycotoxins is reduced withinsaid subject.
 13. The method of claim 12, wherein said administeringcomprises feeding said clay or clay component interlaced yeast cell wallextract incorporated material to said subject.
 14. The method of claim12, wherein said clay or clay component interlaced yeast cell wallextract incorporated material is a liquid.
 15. The method of claim 12,wherein said clay or clay component interlaced yeast cell wall extractincorporated material is a feedstuff.
 16. The method of claim 15,wherein said feedstuff is selected from the group consisting of a TotalMixed Ration (TMR), a forage, a pellet, a concentrate, a premix, grain,distiller grain, molasses, fiber, fodder, grass, hay, kernel, leaves,meal, distiller solubles, and a feed supplement.